VITEK MS

• K Number: DEN130013
• Device Name: VITEK MS
• Manufacturer: BIOMERIEUX, INC.
• Date Cleared: 2013-08-21 ( 231 days)
• Product Code: PEX
• Regulation Number: 866.3361

Intended Use

VITEK MS is a mass spectrometer system using matrix-assisted laser desorption/ionization time to flight (MALDI-TOF) for the identification of microorganisms cultured from human specimens. The VITEK®MS is a qualitative in vitro diagnostic device indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and yeast infections.

Device Description

The VITEK® MS v2.0 system is a system consisting of kit reagents (VITEK MS-CHCA, VITEK MS-FA), VITEK MS-DS target slides, VITEK® MS Prep Station, Knowledge Base, software, and the VITEK®MS (original equipment manufacturer (OEM)-labeled Shimadzu AXIMA® Assurance mass spectrometer). The VITEK® MS v2.0 system includes an OEM-labeled Shimadzu AXIMA® Assurance mass spectrometer linked to a reference database, referred to as Knowledge Base. Matrix assisted laser desorption ionization (MALDI) is the process used to ionize a sample in to the gas phase. A pulsed laser beam is directed on to the sample. Energy from the laser beam desorbs and ionizes the sample. Extraction plates provide high-voltage electrical fields to accelerate the ionized particles upwards through the time-of-flight (TOF) vacuum tube. An ion lens focuses the ions. Deflector plates steer the ions on a path towards the linear detector at the flight-tube. An ion gate blanks out low mass ions (for example, derived from the matrix). The detector detects the ions directly from the sample (lower-molecular weight ions followed by highermolecular weight ions). Ions hitting the detector cause an electrical signal which is recorded. The recorded signal is processed by the software and presented as a spectrum of intensity versus mass, in Daltons (Da). During target ionization, mass spectra within a range of 2,000-20,000 Daltons are recorded in linear positive mode at a laser frequency of 50 Hz. For each interrogation, laser shots at different positions within the target well produce up to 100 mass profiles that are summed into a single, raw mass spectrum. The spectrum is then processed by baseline correction, de-noising, and peak detection to identify well-defined peaks. The list of these significant peaks is subjected to a proprietary process called "mass binning". The processed (binned) data are used to query the Knowledge Base to determine the unknown's taxonomic identity. These results are then provided in the form of a single, species-level (and sometimes subspecies-level) identification, a split (low discrimination) identification with up to four species-level alternatives displayed, or no identification.

Predicate Devices

The relevant section for predicate devices is explicitly listed as "Predicate Device(s) Not Found". Thus, there are no predicate devices to extract.

Reference Devices

Not Found

AI/ML (Artificial Intelligence / Machine Learning)

Yes
The summary explicitly states that "Bin scores from organism spectra are classified based on a supervised machine learning algorithm, known as the 'Advanced Spectrum Classifier' (ASC)".

Therapeutic

No.
The device is an in vitro diagnostic device used for the identification of microorganisms and aids in the diagnosis of infections, not for treating them.

Diagnostic

Yes

The "Intended Use / Indications for Use" section explicitly states, "The VITEK®MS is a qualitative in vitro diagnostic device indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and yeast infections."

SaMD (Software as a Medical Device)

No

The device description explicitly states that the VITEK® MS v2.0 system is a system consisting of kit reagents, target slides, a prep station, software, and a mass spectrometer. This includes significant hardware components beyond just software.

IVD (In Vitro Diagnostic)

Yes, this device is an IVD (In Vitro Diagnostic).

Here's why:

• Explicit Statement: The "Intended Use / Indications for Use" section explicitly states: "The VITEK®MS is a qualitative in vitro diagnostic device indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and yeast infections."
• Intended Use: The device is intended for the identification of microorganisms cultured from human specimens to aid in the diagnosis of infections. This is a classic application of an in vitro diagnostic device.
• Device Description: The description details a system that analyzes biological samples (cultured microorganisms) using a mass spectrometer and a reference database to provide diagnostic information.
• Clinical Studies: The document describes performance studies conducted in clinical microbiology laboratories using patient cultures, which is typical for IVD validation.
• Care Setting: The intended user is clinical microbiology laboratories, which are settings where IVD devices are used.

PCCP (Predetermined Change Control Plan) Authorized

No
The letter mentions a 'Control Plan Authorized (PCCP)' but does not explicitly state that the FDA reviewed and approved or cleared a PCCP for this specific device. The listed points under it describe general submission requirements and risk management activities, not a cleared PCCP.

Overview

Intended Use / Indications for Use

VITEK MS is a mass spectrometer system using matrix-assisted laser desorption/ionization time to flight (MALDI-TOF) for the identification of microorganisms cultured from human specimens.

The VITEK®MS is a qualitative in vitro diagnostic device indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and yeast infections.

Product codes

PEX

Device Description

The VITEK® MS v2.0 system is a system consisting of kit reagents (VITEK MS-CHCA, VITEK MS-FA), VITEK MS-DS target slides, VITEK® MS Prep Station, Knowledge Base, software, and the VITEK®MS (original equipment manufacturer (OEM)-labeled Shimadzu AXIMA® Assurance mass spectrometer).

The VITEK® MS v2.0 system includes an OEM-labeled Shimadzu AXIMA® Assurance mass spectrometer linked to a reference database, referred to as Knowledge Base. Matrix assisted laser desorption ionization (MALDI) is the process used to ionize a sample in to the gas phase. A pulsed laser beam is directed on to the sample. Energy from the laser beam desorbs and ionizes the sample. Extraction plates provide high-voltage electrical fields to accelerate the ionized particles upwards through the time-of-flight (TOF) vacuum tube. An ion lens focuses the ions. Deflector plates steer the ions on a path towards the linear detector at the flight-tube. An ion gate blanks out low mass ions (for example, derived from the matrix). The detector detects the ions directly from the sample (lower-molecular weight ions followed by highermolecular weight ions). Ions hitting the detector cause an electrical signal which is recorded. The recorded signal is processed by the software and presented as a spectrum of intensity versus mass, in Daltons (Da).

During target ionization, mass spectra within a range of 2,000-20,000 Daltons are recorded in linear positive mode at a laser frequency of 50 Hz. For each interrogation, laser shots at different positions within the target well produce up to 100 mass profiles that are summed into a single, raw mass spectrum. The spectrum is then processed by baseline correction, de-noising, and peak detection to identify well-defined peaks. The list of these significant peaks is subjected to a proprietary process called "mass binning". The processed (binned) data are used to query the Knowledge Base to determine the unknown's taxonomic identity. These results are then provided in the form of a single, species-level (and sometimes subspecies-level) identification, a split (low discrimination) identification with up to four species-level alternatives displayed, or no identification.

VITEK MS-CHCA (Alpha-cyano-4-hydroxy-cinnamic acid) is the solution that serves as a matrix which will crystalize with the microbial sample on the target slide spot. 1.0 µl of the matrix is added to the spot with the sample and allowed to dry forming crystals.

The VITEK MS-FA (Formic acid) reagent is used to pre-treat yeast in order to extract protein before the VITEK MS-CHCA matrix is added to the spot containing the sample.

VITEK MS-DS target slides are single-use disposables which contain 3 acquisition groups of 16 sample spots. Each group includes 1 calibration spot. Target slides are for single use only.

The VITEK® MS Prep Station is used to prepare VITEK MS-DS target slides. It consists of a computer workstation equipped with a barcode reader, Touch Screen and Virtual Keyboard.

bioMérieux's VITEK®MS, is the same instrument as the Shimadzu Axima Assurance MALDI-TOF spectrometer. The VITEK®MS is manufactured for bioMérieux by Kratos Analytical (a Shimadzu subsidiary) in Manchester, UK. The VITEK®MS contains a Class 1 laser product containing a Class 3b invisible-light laser. The laser is a 337 nm nitrogen laser, fixed focus.

The Acquisition Station software operates the VITEK®MS instrument to acquire spectral data from each sample. Calibration is an automatic first step in the sample acquisition process. The Acquisition Station consists of a computer workstation equipped with a barcode reader and the Acquisition Station Software v1.4.2. The VITEK®MS is connected to the VITEK® MS Acquisition Station via USB, serial and camera ports. The recorded signal is processed by the Acquisition Station software and presented as a spectrum of intensity versus mass in Daltons (Da). After spectra have been acquired from each sample spot in an acquisition group, the calibration spot is checked again.

The VITEK® MS Analysis Server is the software that manages the VITEK®MS workflow ● and computes VITEK®MS identification results. It is a software component that resides on theMyla™ Server (PC).

Myla™ is a computer application ("Middleware"), based on Web technology, which allows data related to the laboratory workflow, laboratory instruments, Laboratory Information System (LIS), analysis results, etc. to be grouped together. Myla™ interfaces between the bioMérieux instruments connected to the application (e.g., VITEK®MS) and the Laboratory Information System (LIS). Myla™ manages the VITEK®MS workflow and computes the identification results with the use of a computation engine and organism knowledge bases.

Knowledge Base: The reference database for the VITEK®MS system includes data representing 755 taxa, including 645 bacteria and 110 fungi. Each species group is represented by an average of 10 isolates (range 2 - 475). In order to capture the degree of acceptable variation within spectra from the same species, each reference isolate was grown on multiple media types under several growth conditions. The raw spectra were then acquired by more than one technician using multiple instruments. This process resulted in an average of 40 reference spectra per species.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Bin scores from organism spectra are classified based on a supervised machine learning algorithm, known as the "Advanced Spectrum Classifier" (ASC), which is derived from the distribution of weighted bin scores from all spectra for a given species.

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Knowledge Base: The reference database for the VITEK®MS system includes data representing 755 taxa, including 645 bacteria and 110 fungi. Each species group is represented by an average of 10 isolates (range 2 - 475). In order to capture the degree of acceptable variation within spectra from the same species, each reference isolate was grown on multiple media types under several growth conditions. The raw spectra were then acquired by more than one technician using multiple instruments. This process resulted in an average of 40 reference spectra per species.

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Proficiency Study: Operators at each site were trained in target slide preparation, instrument use, and result review. Each operator was required to demonstrate proficiency by successfully analyzing a masked panel of organisms consisting of 10 isolates representing common aerobic and anaerobic Gram-positive and Gram-negative bacteria and yeasts.

Challenge Study:
Study type: Challenge study
Sample size: Three challenge panels consisting of 100 strains each were assembled; each of the panels was tested at three of the clinical trial sites, for a total of 300 isolates.
Key results:
Correct Identification (ID) for Genus & Species (1 choice): 91.7% (825/900)
Low Discrimination (>1 choice in same genus): 4.4% (40/900)
Combined Correct (1 choice + >1 choice in same genus): 96.1% (865/900)
Discordant: 0.2% (2/900)
No Identification: 3.7% (33/900)

Prospective Clinical Study:
Study type: Prospective Clinical Study
Sample size: Total of 7068 results from patient cultures (2256 Gram-positive bacteria, 3656 Gram-negative bacteria, 1156 Yeasts).
Data source: Patient cultures from five clinical microbiology laboratories in the United States.
Reference method: Molecular sequencing supplemented as needed by additional molecular sequencing and/or biochemical testing.
Key results:
Overall Combined Correct Single Choice and Low Discrim. Correct Genus: 93.6% (6614/7068), 95% CI [93.0 ; 94.1]%
Gram-positive bacteria: Combined Correct 93.5% (2110/2256), 95% CI [92.4 ; 94.5]%
Gram-negative bacteria: Combined Correct 92.8% (3391/3656), 95% CI [91.9 ; 93.6]%
Yeasts: Combined Correct 96.3% (1113/1156), 95% CI [95.0 ; 97.3]%

Key Metrics

Reproducibility: 99.7% (598/600) with a CI of [98.8 ; 99.9 %] for organism specific and overall rate of correct identification.

LoD:
Minimum LoD: 2 McFarland for S. aureus and 6 McFarland for C. jeikeium for bacteria, and 7 McFarland for yeast (C. glabrata).
In terms of CFU/spot (1 ul): 10^6 CFU/spot for bacteria and 10^4 CFU/spot for yeast.

Analytical Specificity (Threshold): A threshold of 60% indicates that an unknown isolate's overall score is within the range of scores generated by known examples of that species, but is outside the range of scores generated by every other species in the database.

Assay Cut-off:
Single identification: displayed with confidence value of 60 to 99.9 when one significant organism or organism group is retained.
Low Discrimination identifications: displayed when more than one significant organism or organism group are retained, but not for more than 4 organisms. Sum of confidence values equals 100.
Non-identified: When more than 4 organisms or organism groups are found, or when no match is found.

Clinical Performance (Overall):
Correct Single Choice (no. results): 87.5% (6184/7068)
Low Discrim.* Correct Genus (no. results): 6.1% (430/7068)
Combined Correct Single Choice and Low Discrim. Correct Genus (no. results): 93.6% (6614/7068), 95% CI [93.0 ; 94.1]%
Single Choice Incorrect ID (no. results): 0.8% (54/7068)
Low Discrim. Incorrect Genus (no. results): 0.2% (12/7068)
Low Discrim. Multiple Genera (no. results): 2.2% (159/7068)
No ID (no. results): 3.2% (229/7068)

Specific for Low Discrimination:
Of the 430 low discrimination same genus results, 426 (99.1%) had the correct species present and 4 (0.9%) did not have the correct species present.
Of the 159 low discrimination multiple genera results, 140 (88.0%) had the correct species present and 19 (12.0%) did not have the correct species present.

Mixed Culture Study:
68.2% (30/44) of cases, an identification of the more concentrated species in single choice.
11.4% (5/44) of cases, an identification of the less concentrated species in single choice.
20.5% (9/44) of cases, a Low Discrimination between both tested species.

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

Regulation Number and Section

§ 866.3361 Mass spectrometer system for clinical use for the identification of microorganisms.

(a)
Identification. A mass spectrometer system for clinical use for the identification of microorganisms is a qualitative in vitro diagnostic device intended for the identification of microorganisms cultured from human specimens. The device is comprised of an ionization source, a mass analyzer, and a spectral database. The device is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and fungal infections.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Premarket notification submissions must include detailed documentation for device software, including, but not limited to, standalone software applications and hardware-based devices that incorporate software.
(2) Premarket notification submissions must include database implementation methodology, construction parameters, and quality assurance protocols.
(3) A detailed explanation of the interpretation of results and acceptance criteria must be included in the device's 21 CFR 809.10(b)(9) compliant labeling.
(4) As part of the risk management activities performed as part of your 21 CFR 820.30 design controls, you must document an appropriate end user device training program that will be offered as part of your efforts to mitigate the risk of failure to correctly operate the instrument.
(5) Premarket notification submissions must include details on the appropriate end user device training program that will be offered while marketing the device.

Summary

0

510(k) DECISION SUMMARY

A. 510(k) Number:

K124067

B. Purpose for Submission:

De novo request for evaluation of automatic class III designation for the VITEK®MS.

C. Measurand:

Abiotrophia defectiva	Campylobacter coli	Clostridium perfringens
Achromobacter denitrificans1	Campylobacter jejuni	Clostridium ramosum
Achromobacter xylosoxidans1	Candida albicans	Corynebacterium jeikeium
Acinetobacter baumannii
complex	Candida dubliniensis	Cronobacter sakazakii
Acinetobacter haemolyticus	Candida famata	Cryptococcus neoformans
Acinetobacter junii	Candida glabrata	Edwardsiella hoshinae
Acinetobacter lwoffii	Candida guilliermondii	Edwardsiella tarda
Actinomyces meyeri	Candida haemulonii	Eikenella corrodens
Actinomyces neuii	Candida inconspicua	Elizabethkingia
meningoseptica
Actinomyces odontolyticus	Candida intermedia	Enterobacter aerogenes
Aerococcus viridans	Candida kefyr	Enterobacter asburiae4
Aeromonashydrophila/caviae2	Candida krusei	Enterobacter cloacae4
Aeromonas sobria2	Candida lambica	Enterobacter cancerogenus
Aggregatibacter
actinomycetemcomitans	Candida lipolytica	Enterobacter gergoviae
Aggregatibacter aphrophilus	Candida lusitaniae	Enterococcus avium
Aggregatibacter segnis	Candida norvegensis	Enterococcus casseliflavus
Alcaligenes faecalis ssp
faecalis	Candida parapsilosis	Enterococcus durans
Bacteroides caccae	Candida pelliculosa	Enterococcus faecalis
Bacteroides fragilis	Candida rugosa	Enterococcus faecium
Bacteroides ovatus	Candida tropicalis	Enterococcus gallinarum
Bacteroides thetaiotaomicron	Candida utilis	Escherichia coli5
Bacteroides uniformis	Candida zeylanoides	Escherichia fergusonii
Bacteroides vulgatus	Chryseobacterium indologenes	Escherichia hermannii
Bordetella parapertussis	Citrobacter amalonaticus	Ewingella americana
Bordetella pertussis	Citrobacter braakii3	Finegoldia magna
Brevundimonas diminuta	Citrobacter freundi3	Fusobacterium necrophorum
Burkholderia multivorans	Citrobacter youngae3	Fusobacterium nucleatum
	Citrobacter koseri	Gardnerella vaginalis
	Clostridium clostridioforme	Gemella haemolysans
	Clostridium difficile
Gemella morbillorum	Prevotella buccae	Staphylococcus
Geotrichum capitatum	Prevotella denticola	saprophyticus
Granulicatella adiacens	Prevotella intermedia	Staphylococcus schleiferi
Haemophilus influenzae	Prevotella melaninogenica	Staphylococcus sciuri
Haemophilus parahaemolyticus	Propionibacterium acnes	Staphylococcus simulans
Haemophilus parainfluenzae	Proteus mirabilis	Staphylococcus warneri
Hafnia alvei	Proteus penneri7	Stenotrophomonas
Kingella denitrificans	Proteus vulgaris7	maltophilia
Kingella kingae	Providencia rettgeri	Streptococcus agalactiae
Klebsiella oxytoca	Providencia stuartii	Streptococcus anginosus
Klebsiella pneumoniae	Pseudomonas aeruginosa	Streptococcus constellatus
Kodamaea ohmeri	Pseudomonas fluorescens	Streptococcus
Lactococcus garvieae	Pseudomonas putida	dysgalactiae
Lactococcus lactis ssp lactis	Pseudomonas stutzeri	Streptococcus gallolyticus
Leclercia adecarboxylata	Ralstonia pickettii	ssp gallolyticus
Legionella pneumophila	Raoultella ornithinolytica	Streptococcus infantarius
Leuconostoc mesenteroides	Raoultella planticola	ssp coli
Leuconostoc pseudomesenteroides	Rhizobium radiobacter	Streptococcus infantarius
Listeria monocytogenes	Rhodotorula mucilaginosa	ssp infantarius
Malassezia furfur	Rothia mucilaginosa	Streptococcus intermedius
Malassezia pachydermatis	Saccharomyces cerevisiae	Streptococcus
Micrococcus luteus/lylae	Salmonella group6	mitis/Streptococcus oralis
Mobiluncus curtisii	Serratia fonticola	Streptococcus mutans
Moraxella (Branhamella)	Serratia liquefaciens	Streptococcus pneumoniae
catarrhalis	Serratia marcescens	Streptococcus pyogenes
Morganella morganii	Serratia odorifera	Streptococcus salivarius
Neisseria cinerea	Sphingobacterium multivorum	ssp salivarius
Neisseria gonorrhoeae6	Sphingobacterium spiritivorum	Streptococcus sanguinis
Neisseria meningitidis	Sphingomonas paucimobilis	Trichosporon asahii
Neisseria mucosa	Staphylococcus aureus	Trichosporon inkin
Ochrobactrum anthropi	Staphylococcus capitis	Trichosporon mucoides
Oligella ureolytica	Staphylococcus cohnii ssp	Vibrio cholerae
Oligella urethralis	cohnii	Vibrio parahaemolyticus
Pantoea agglomerans	Staphylococcus cohnii ssp	Vibrio vulnificus
Parvimonas micra	urealyticus	Yersinia enterocolitica
Pasteurella multocida	Staphylococcus epidermidis	Yersinia frederiksenii
Pediococcus acidilactici	Staphylococcus haemolyticus	Yersinia intermedia
Peptoniphilus asaccharolyticus	Staphylococcus hominis ssp	Yersinia kristensenii
Peptostreptococcus anaerobius	hominis	Yersinia
Prevotella bivia	Staphylococcus lugdunensis	pseudotuberculosis

1

• 1. Achromobacter denitrificans and Achromobacter xylosoxidans identifications should be considered as a slashline result, Achromobacter denitrificans/ Achromobacter xylosoxidans.
• 2. Aeromonas hydrophila/caviae and Aeromonas sobria should be considered as an Aeromonas species group identification.

2

• 3. Citrobacter freundii. Citrobacter braakii and Citrobacter youngae should be considered as Citrobacter freundii complex.
• 4. Enterobacter cloacae and Enterobacter asburiae identifications should be considered as a slashline result, Enterobacter cloacae/ Enterobacter asburiae.
• 5. Shigella species and E. coli O157 are identified as Escherichia coli. Confirmatory tests are required to differentiate Escherichia coli from Shigella species or E. coli 0157.
• 6. Confirmatory tests recommended for Neisseria gonorrhea and Salmonella species.
• 7. Proteus penneri and Proteus vulgaris identifications should be considered as a slashline result, Proteus penneri/ Proteus vulgaris.

D. Type of Test:

A mass spectrometer system for clinical use for the identification of microorganisms is a qualitative in vitro diagnostic device intended for the identification of microorganisms cultured from human specimens. The device is comprised of an ionization source, a mass analyzer and a spectral database. The device is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and fungal infections.

E. Applicant:

bioMérieux, Inc.

F. Proprietary and Established Names:

Trade Name: VITEK®MS

Common Name: VITEK MS

G. Regulatory Information:

• 1. Regulation Number: 21 CFR 866. 3361
• 2. Classification: Class II (special controls)
• 3. Product code: PEX
• 4. Panel: Microbiology (83)

H. Intended Use:

• 1. Intended use(s):
     VITEK MS is a mass spectrometer system using matrix-assisted laser desorption/ionization time to flight (MALDI-TOF) for the identification of microorganisms cultured from human specimens.

3

The VITEK®MS is a qualitative in vitro diagnostic device indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and yeast infections.

The following organisms are claimed:

Abiotrophia defectiva	Candida inconspicua	Enterococcus casseliflavus
Achromobacter denitrificans1	Candida intermedia	Enterococcus durans
Achromobacter xylosoxidans1	Candida kefyr	Enterococcus faecalis
Acinetobacter baumannii	Candida krusei	Enterococcus faecium
complex	Candida lambica	Enterococcus gallinarum
Acinetobacter haemolyticus	Candida lipolytica	Escherichia coli5
Acinetobacter junii	Candida lusitaniae	Escherichia fergusonii
Acinetobacter lwoffii	Candida norvegensis	Escherichia hermannii
Actinomyces meyeri	Candida parapsilosis	Ewingella americana
Actinomyces neuii	Candida pelliculosa	Finegoldia magna
Actinomyces odontolyticus	Candida rugosa	Fusobacterium necrophorum
Aerococcus viridans	Candida tropicalis	Fusobacterium nucleatum
Aeromonashydrophila/caviae2	Candida utilis	Gardnerella vaginalis
Aeromonas sobria2	Candida zeylanoides	Gemella haemolysans
Aggregatibacter	Chryseobacterium indologenes	Gemella morbillorum
actinomycetemcomitans	Citrobacter amalonaticus	Geotrichum capitatum
Aggregatibacter aphrophilus	Citrobacter braakii3	Granulicatella adiacens
Aggregatibacter segnis	Citrobacter freundi3	Haemophilus influenzae
Alcaligenes faecalis ssp	Citrobacter koseri	Haemophilus
parahaemolyticus
faecalis	Citrobacter youngae3	Haemophilus parainfluenzae
Bacteroides caccae	Clostridium clostridioforme	Hafnia alvei
Bacteroides fragilis	Clostridium difficile	Kingella denitrificans
Bacteroides ovatus	Clostridium perfringens	Kingella kingae
Bacteroides thetaiotaomicron	Clostridium ramosum	Klebsiella oxytoca
Bacteroides uniformis	Corynebacterium jeikeium	Klebsiella pneumoniae
Bacteroides vulgatus	Cronobacter sakazakii	Kodamaea ohmeri
Bordetella parapertussis	Cryptococcus neoformans	Lactococcus garvieae
Bordetella pertussis	Edwardsiella hoshinae	Lactococcus lactis ssp lactis
Brevundimonas diminuta	Edwardsiella tarda	Leclercia adecarboxylata
Burkholderia multivorans	Eikenella corrodens	Legionella pneumophila
Campylobacter coli	Elizabethkingia meningoseptica	Leuconostoc mesenteroides
Campylobacter jejuni	Enterobacter aerogenes	Leuconostoc
pseudomesenteroides
Candida albicans	Enterobacter asburiae4	Listeria monocytogenes
Candida dubliniensis	Enterobacter cancerogenus	Malassezia furfur
Candida famata	Enterobacter cloacae4	Malassezia pachydermatis
Candida glabrata	Enterobacter gergoviae
Candida guilliermondii	Enterococcus avium
Candida haemulonii
Micrococcus luteus/lylae	Pseudomonas putida	Stenotrophomonas
Mobiluncus curtisii	Pseudomonas stutzeri	maltophilia
Moraxella (Branhamella)	Ralstonia pickettii	Streptococcus agalactiae
catarrhalis	Raoultella ornithinolytica	Streptococcus anginosus
Morganella morganii	Raoultella planticola	Streptococcus constellatus
Neisseria cinerea	Rhizobium radiobacter	Streptococcus
Neisseria gonorrhoeae6	Rhodotorula mucilaginosa	dysgalactiae
Neisseria meningitidis	Rothia mucilaginosa	Streptococcus gallolyticus
Neisseria mucosa	Saccharomyces cerevisiae	ssp gallolyticus
Ochrobactrum anthropi	Salmonella group6	Streptococcus infantarius
Oligella ureolyticaOligella	Serratia fonticola	ssp coli
urethralis	Serratia liquefaciens	Streptococcus infantarius
Pantoea agglomerans	Serratia marcescens	ssp infantarius
Parvimonas micra	Serratia odorifera	Streptococcus intermedius
Pasteurella multocida	Sphingobacterium multivorum	Streptococcus
Pediococcus acidilactici	Sphingobacterium spiritivorum	mitis/Streptococcus oralis
Peptoniphilus	Sphingomonas paucimobilis	Streptococcus mutans
asaccharolyticus	Staphylococcus aureus	Streptococcus pneumoniae
Peptostreptococcus	Staphylococcus capitis	Streptococcus pyogenes
anaerobius	Staphylococcus cohnii ssp	Streptococcus salivarius
Prevotella bivia	cohnii	ssp salivarius
Prevotella buccae	Staphylococcus cohnii ssp	Streptococcus sanguinis
Prevotella denticola	urealyticus	Trichosporon asahii
Prevotella intermedia	Staphylococcus epidermidis	Trichosporon inkin
Prevotella melaninogenica	Staphylococcus haemolyticus	Trichosporon mucoides
Propionibacterium acnes	Staphylococcus hominis ssp	Vibrio cholerae
Proteus mirabilis7	hominis	Vibrio parahaemolyticus
Proteus penneri7	Staphylococcus lugdunensis	Vibrio vulnificus
Proteus vulgaris	Staphylococcus saprophyticus	Yersinia enterocolitica
Providencia rettgeri	Staphylococcus schleiferi	Yersinia frederiksenii
Providencia stuartii	Staphylococcus sciuri	Yersinia intermedia
Pseudomonas aeruginosa	Staphylococcus simulans	Yersinia kristensenii
Pseudomonas fluorescens	Staphylococcus warneri	Yersinia
		pseudotuberculosis

4

• 1. Achromobacter denitrificans and Achromobacter xylosoxidans identifications should be considered as a slashline result, Achromobacter denitrificans/ Achromobacter xylosoxidans.
• 2. Aeromonas hydrophila/caviae and Aeromonas sobria should be considered as an Aeromonas species group identification.
• 3. Citrobacter freundii, Citrobacter braakii and Citrobacter youngae should be considered as Citrobacter freundii complex.
• 4. Enterobacter cloacae and Enterobacter asburiae identifications should be considered as a slashline result, Enterobacter cloacae/ Enterobacter asburiae.
• 5. Shigella species and E. coli 0157 are identified as Escherichia coli. Confirmatory tests are required to differentiate Escherichia coli from Shigella species or E. coli 0157.

5

• 6. Confirmatory tests recommended for Neisseria gonorrhea and Salmonella species.
• 7. Proteus penneri and Proteus vulgaris identifications should be considered as a slashline result, Proteus penneri/ Proteus vulgaris.
• 2. Indication(s) for use: Same as intended use.
• 3. Special conditions for use statement(s):

The VITEK®MS is for prescription use only in accordance with 21 CFR 801.109.

• 4. Special instrument requirements:
     VITEK® MS: Shimadzu AXIMA® Assurance mass spectrometer

VITEK®MS Prep Station

VITEK MS-DS Target Slides

Reagents:

• VITEK MS-CHCA (Alpha-cyano-4-hydroxy-cinnamic acid) solution ●
• VITEK MS-FA (Formic acid) reagent ●

Database: VITEK® MS V2.0 Knowledge Base

Software:

• VITEK®MS Acquisition Station ●
• VITEK® MS Prep Station ●
• Myla™ ●

I. Device Description:

The VITEK® MS v2.0 system is a system consisting of kit reagents (VITEK MS-CHCA, VITEK MS-FA), VITEK MS-DS target slides, VITEK® MS Prep Station, Knowledge Base, software, and the VITEK®MS (original equipment manufacturer (OEM)-labeled Shimadzu AXIMA® Assurance mass spectrometer).

The VITEK® MS v2.0 system includes an OEM-labeled Shimadzu AXIMA® Assurance mass spectrometer linked to a reference database, referred to as Knowledge Base. Matrix assisted laser desorption ionization (MALDI) is the process used to ionize a sample in to the gas phase. A pulsed laser beam is directed on to the sample. Energy from the laser beam desorbs and ionizes the sample. Extraction plates provide high-voltage electrical fields to accelerate the ionized particles upwards through the time-of-flight (TOF) vacuum tube. An ion lens focuses the ions. Deflector plates steer the ions on a path towards the linear detector at the flight-tube. An ion gate blanks out low mass ions (for example, derived from the matrix). The detector detects the ions directly from the sample (lower-molecular weight ions followed by highermolecular weight ions). Ions hitting the detector cause an electrical signal which is recorded. The

6

recorded signal is processed by the software and presented as a spectrum of intensity versus mass, in Daltons (Da).

During target ionization, mass spectra within a range of 2,000-20,000 Daltons are recorded in linear positive mode at a laser frequency of 50 Hz. For each interrogation, laser shots at different positions within the target well produce up to 100 mass profiles that are summed into a single, raw mass spectrum. The spectrum is then processed by baseline correction, de-noising, and peak detection to identify well-defined peaks. The list of these significant peaks is subjected to a proprietary process called "mass binning". The processed (binned) data are used to query the Knowledge Base to determine the unknown's taxonomic identity. These results are then provided in the form of a single, species-level (and sometimes subspecies-level) identification, a split (low discrimination) identification with up to four species-level alternatives displayed, or no identification.

VITEK MS-CHCA (Alpha-cyano-4-hydroxy-cinnamic acid) is the solution that serves as a matrix which will crystalize with the microbial sample on the target slide spot. 1.0 µl of the matrix is added to the spot with the sample and allowed to dry forming crystals.

The VITEK MS-FA (Formic acid) reagent is used to pre-treat yeast in order to extract protein before the VITEK MS-CHCA matrix is added to the spot containing the sample.

VITEK MS-DS target slides are single-use disposables which contain 3 acquisition groups of 16 sample spots. Each group includes 1 calibration spot. Target slides are for single use only.

The VITEK® MS Prep Station is used to prepare VITEK MS-DS target slides. It consists of a computer workstation equipped with a barcode reader, Touch Screen and Virtual Keyboard.

bioMérieux's VITEK®MS, is the same instrument as the Shimadzu Axima Assurance MALDI-TOF spectrometer. The VITEK®MS is manufactured for bioMérieux by Kratos Analytical (a Shimadzu subsidiary) in Manchester, UK. The VITEK®MS contains a Class 1 laser product containing a Class 3b invisible-light laser. The laser is a 337 nm nitrogen laser, fixed focus.

The Acquisition Station software operates the VITEK®MS instrument to acquire spectral data from each sample. Calibration is an automatic first step in the sample acquisition process. The Acquisition Station consists of a computer workstation equipped with a barcode reader and the Acquisition Station Software v1.4.2. The VITEK®MS is connected to the VITEK® MS Acquisition Station via USB, serial and camera ports. The recorded signal is processed by the Acquisition Station software and presented as a spectrum of intensity versus mass in Daltons (Da). After spectra have been acquired from each sample spot in an acquisition group, the calibration spot is checked again.

The VITEK® MS Analysis Server is the software that manages the VITEK®MS workflow ● and computes VITEK®MS identification results. It is a software component that resides on theMyla™ Server (PC).

Myla™ is a computer application ("Middleware"), based on Web technology, which allows data

7

related to the laboratory workflow, laboratory instruments, Laboratory Information System (LIS), analysis results, etc. to be grouped together. Myla™ interfaces between the bioMérieux instruments connected to the application (e.g., VITEK®MS) and the Laboratory Information System (LIS). Myla™ manages the VITEK®MS workflow and computes the identification results with the use of a computation engine and organism knowledge bases.

Knowledge Base: The reference database for the VITEK®MS system includes data representing 755 taxa, including 645 bacteria and 110 fungi. Each species group is represented by an average of 10 isolates (range 2 - 475). In order to capture the degree of acceptable variation within spectra from the same species, each reference isolate was grown on multiple media types under several growth conditions. The raw spectra were then acquired by more than one technician using multiple instruments. This process resulted in an average of 40 reference spectra per species.

J. Standard/Guidance Document Referenced (if applicable):

	Standards	Recognition	Standards Title	Date
	No.	Number
		(FDA)
1	C50-A		Mass Spectrometry in the Clinical	10/29/2007
			Laboratory: General Principles and Guidance;
			Approved Guideline, 1st Edition
2	MM09A	7-123	Nucleic Acid Sequencing Methods in	12/20/2004
			Diagnostic Laboratory Medicine; Approved
			Guideline, 1st Edition
3	MM-18A	7-192	Criteria for Identification of Bacteria and	4/28/2008
			Fungi by DNA Target Sequencing: Approved
			Guideline, 1st Edition
4	M35-A2	7-197	Abbreviated Identification of Bacteria and	11/24/2008
			Yeast; Approved Guideline, 2nd Edition
ನ	EP9-A2-IR	7-92	Method Comparison and Bias Estimation	7/30/2010
			Using Patient Samples; Approved Guideline;
			2" Edition (Interim Revision)
6	EP12-A2	7-152	User Protocol for Evaluation f Qualitative	09/09/2008
			Test Performance (2nd edition)

Standards References

Guidance Documents Referenced

	Title	Date
1	FDA/CDRH/ODE Evaluation of Automatic
Class III Designation, Guidance for Industry
and CDRH Staff	4/19/1998
2	Statistical Guidance on Reporting Results From
Studies Evaluating Diagnostic Tests	3/13/2007

K. Test Principle:

8

The VITEK®MS system is based on a matrix-assisted laser desorption ionization-time of flight mass spectrometer (MALDI-TOF MS). The colony is mixed with a saturated matrix solution and forms crystals. The ionization of this mixture by the laser induces the desorption and transfer of protons from photo-excited matrix to analyte to form a protonated molecule. During the analysis process, proteins are ionized without fragmentation by the coordinated action of the laser and the small organic acids of the matrix and separated on the basis of their mass-to-charge ratios, a process which results in a characteristic mass spectral profile. Microbial identification is based on the comparison of the protein spectrum generated from intact whole bacterial cells to the knowledge database of species-specific reference protein profiles using a particular algorithm.

L. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Reproducibility

A reproducibility study was conducted at three external sites with a panel of 10 organisms. Each organism was tested in duplicate in each of two runs on the VITEK®MS, on five separate days, at each trial site for a total of 20 replicates per reproducibility organism. Samples were tested in both sequential and randomized order. Three different lots of VITEK MS-CHCA, VITEK MS-FA and VITEK MS-DS target slides were included in the study.

For all sites combined, the reproducibility of the VITEK®MS organism specific and overall rate of correct identification was 99.7% (598/600) with a CI of [98.8 ; 99.9 %].

b. Linearity/assay reportable range:

Not applicable, qualitative assay.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Calibrator:

E. coli ATCC 8739 is used to as a calibrator. This organism is deposited with VITEK MS-CHCA matrix on positions: xA1, xB1, xC1, of the VITEK MS-DS target slides depending on the number of samples tested (one calibrator per acquisition group of 16 spots). The VITEK "MS goes to the calibration spot in an acquisition group and performs a calibration. If the calibration passes, the instrument goes to the first spot in the acquisition group. If the calibration fails, an error is reported and VITEK®MS proceeds to the next acquisition group without collecting sample spectra. After spectra have been acquired from each sample spot in an acquisition group, the calibration spot is checked again. The calibration sample should provide E. coli identification at 99.9% in Myla™ software.

Controls:

Two organisms are used for positive quality control. Matrix alone is used for the negative

9

control. The quality control strains are as follows:

	Expected Result
Enterobacter aerogenes ATCC® 13048	Enterobacter aerogenes
Candida glabrata ATCC MYA-2950	Candida glabrata
Negative Control (matrix)	No Identification

NOTE: If the negative control does not give the expected result, users need to visually inspect the surface of the VITEK MS-DS target slides to ensure the slides are clean and repeat testing with new slide.

• d. Assay cut-off:
  After the calibration is accepted for an acquisition group, the VITEK®MS acquires the spectra for the samples in that group. The instrument then scans the sample to acquire data. As the spectrum is acquired for each target spot, it is visible in the Spectrum Display on the Acquisition Screen with the number of profiles increasing as they are collected. A single profile is generated by 5 laser shots. The goal is to achieve 100 acceptable profiles, while 30 is the minimum number of acceptable profiles. When sufficient data has been acquired, the spectrum data is passed to the Analysis Server for analysis and the VITEK®MS goes to the next spot in the acquisition group.

A perfect match between the spectrum and the unique spectrum of a single organism or organism group would provide a percent probability of 99.9. Results are displayed as follows:

• . A single identification is displayed with confidence value of 60 to 99.9 when one significant organism or organism group is retained.
• Low Discrimination identifications are displayed when more than one significant . organism or organism group are retained, but not for more than 4 organisms. In this case, the sum of confidence values is equal to 100.
• . When more than 4 organisms or organism groups are found, the organism is considered as non-identified. In this case, a list of possible organisms is displayed and the sum of confidence values is less than 100.
• . When no match is found, the organism is considered as non-identified Uunclaimed identification

A symbol 'U' may appear next to some organism identifications. This VITEK MS identification indicates that the VITEK®MS result is a non-clinically validated organism. In the interest of public health, these organisms are displayed in the VITEK MS report as a means of directing the required additional laboratory testing. Identification of nonclinically validated organisms must be performed with an alternate laboratory method. Results for non-clinically validated organisms cannot be transmitted from the VITEK MS to the laboratory information system.

10

Non-clinically validated organisms include:

• · Organisms with insufficient clinical performance data.
• · Organisms not found in human clinical samples as reported in the scientific literature.
• e. Detection limit (LoD)

For the VITEK®MS System, the LoD study demonstrated that the LoD is different in terms of McFarland (McF) measurement depending of the tested species (i.e., S.aureus, P. aeruginosa, E.coli, C.jeikeium, and C. glabrata). The minimum LoD is from 2 to 6 McF S. aureus and C. jeikeium respectively and 7 McF for yeast (C. glabrata). The LoD study demonstrated that applying an insufficient quantity of colony usually results in no spectra being acquired. In terms of colony forming units (CFU)/spot (1 ul), the limit of detection is 10° CFU/spot for bacteria and 10+ CFU/spot for yeast. Applying too much colony may cause suboptimal performance of the system. If an excessive quantity of colony is applied, the cells may not suspend well in the matrix suspension and may impact the extraction process and the subsequent crystal formation by the matrix. A 1 ul loop should be used to pick up part of a suitable colony (i.e., approximately 3 mm in size).

• f. Analytical specificity:
  Analytical specificity was assessed using two processes:

• 1. Database development: For each reference species spectrum in the database, signal preprocessing and peak detection was performed to identify peaks. Peaks in the mass spectrum between 3,000 and 17,000 Daltons were divided into 1300 pre-defined intervals called "bins". This process was replicated for each of the reference species thus creating a matrix with a species-specific weight for each of the 1300 bins. Bin scores from organism spectra are classified based on a supervised machine learning algorithm, known as the "Advanced Spectrum Classifier" (ASC), which is derived from the distribution of weighted bin scores from all spectra for a given species. By examining the ASC scores for all claimed species, it was determined that a threshold of 60% indicates that an unknown isolate's overall score is within the range of scores generated by known examples of that species, but is outside the range of scores generated by every other species in the database.
     Once an unknown organism's raw spectrum is acquired by the mass spectrometer it goes through pre-processing and mass binning as described above. The bin scores then go through an iterative process whereby the score within each bin is multiplied by the weighted bin value for each reference species in the Knowledge Base. The sum of the weighted bin scores is then calculated and used to determine the confidence value of the unknown relative to each reference species. After confidence values are obtained, the list of possible organisms is reduced using a decision analysis protocol

11

which is performed in order to retain only organism confidence values with scores above the predefined cut-off of a 60% confidence level and within a pre-defined ASC score tolerance. Finally, the resulting organism list is reported. In the event that there are more than four species on this list or if no species are on the list, a result of "no identification" is reported.

• 2. Analytical Specificity Study: To determine the discriminatory power of the VITEK "MS was evaluated with organisms that are closely related within a group and multiple strains of the same organism. Forty-three organism pairs representing 18 organism groups were evaluated in the study. This data set included 359 individual results. Overall, there were no specific trends or remarkable cross-reactivity to be noted in these results. Of the 18 organism groups evaluated, 12 groups had no unexpected results, with the VITEK®MS identification matching the reference identification. In the remaining six organism groups, the majority of the results matched the expected results. Exceptions are described below:
  • For the Cronobacter/Enterobacter group, there were six discrepant results in the ● set of 36 tests.
  • For the Enterococcus group, there was one discrepant result in the set of 21 tests. ●
  • For the Klebsiella/Raoultella group, there were two discrepant results in the set of ● 19 tests.
  • For the Moraxella group, there was one discrepant result in the set of six tests.
  • For the Morganella/Proteus group, there were three discrepant results in the set of 23 tests.
  • For the Staphylococcus group, there were four discrepant results in the set of 58 tests.

g. Sample stability studies

Sample stability studies of prepared slides were conducted using VITEK MS-DS target slides. Slides were tested at time zero and 24, 48, 72 and 96 hours after initial spotting. (Time zero means that slides were tested in the VITEK "MS directly after the spotting.) For each time tested, 48 strains (bacteria and yeast) were tested in duplicate. Prepared VITEK MS-DS target slides must be tested within 48 hours. Prepared slides should be stored at room temperature until they are tested.

h. Stability studies (reagents, slides)

Reagents - Shelf life and storage conditions:

• 1. VITEK MS-CHCA matrix (Ref. 411071) has a shelf-life of 365 days at 2-8° C in the packaging box. The VITEK MS-CHCA matrix is stable:
  • For one week after opening and storage at 2-8 ° C protected from light (in their ● original boxes).
  • . For one week at ambient temperature (on the worktop, without protection from light) having opened the tube for up to 5 hours.

Note: The tube should be resealed after each series of CHCA matrix depositions.

12

• 2. The VITEK MS-FA (Ref. 411072) reagent has a shelf-life of 365 days at 2-8° C in the packaging box. The VITEK MS-FA reagent is stable for two weeks after opening with recommended storage at 2-8 ℃.
• 3. VITEK MS-DS target slides have a shelf life of 9 months at 15-25 ° C temperature.
• i. Carry-over Contamination

A study to evaluate cross contamination and carry-over was conducted with a panel of 11 strains belonging to 11 species. High positive, moderate positive and negative (matrix) samples were evaluated over multiple test runs alternating sample types. No cross contamination or carry-over was observed as all negative spots remained negative after the run.

• j. Media Requirements:
  VITEK®MS identification performance obtained on different media from three suppliers was evaluated. Organisms were inoculated onto different media according to their growth requirements and incubated in appropriate growth conditions. The media listed below have been validated and are included in the certificate of compatibility.

| Culture
Media | bioMérieux
Reference |
|-----------------------------------------------------|-------------------------|
| Columbia blood agar with 5% sheep blood | 43041 / 43049 |
| Trypticase soy agar with 5% sheep blood | 43001 / 43009 |
| Trypticase soy agar | 43011 / 43019 |
| Chocolate polyvitex agar | 43101 / 43109 |
| Campylosel agar | 43361 |
| MacConkey agar* | 43141 / 43149 |
| Modified Sabouraud dextrose agar (glucose: 20 g/l ) | 42066 |
| chromID CPS | 43541 / 43549 |

• Use of this medium from some suppliers may show less than optimal performance.

k. Culture Age:

The recommended culture incubation time for testing bacteria and yeast with the VITEK MS organisms was generated during the building of the VITEK®MS knowledge base. Organisms were inoculated onto different media from three suppliers according to their growth requirements and incubated in appropriate conditions for 24 to 72 hours. For measurement in the VITEK MS, bactiera and yeast growth must between 24 to 72 hours.

13

2. Comparison studies:

• a. Method comparison with predicate device:
  Not applicable. Refer to the Clinical Studies section of this document.

• b. Matrix comparison:
  Not applicable.

• 3. Clinical studies:

• Clinical Sensitivity a.

Proficiency:

Prior to initiation of the clinical study, operators at each site were trained in target slide preparation, instrument use, and result review. Each operator was required to demonstrate proficiency by successfully analyzing a masked panel of organisms consisting of 10 isolates representing common aerobic and anaerobic Gram-positive and Gram-negative bacteria and yeasts.

Challenge:

A challenge study was conducted as part of the clinical trial. Three challenge panels consisting of 100 stains each were assembled; each of the panels was tested at three of the clinical trial sites.

| Total
Performance | Number
of
Isolates | Correct Identification (ID) | | | Discordant1 | No
Identification2 |
|----------------------|--------------------------|-------------------------------------------------|-------------------------------------------------|---------------------------------------------------------|---------------|-----------------------|
| | | Correct for
Genus &
Species
(1 choice) | Low
Discrim.
(>1 choice in
same genus) | Combined
(1 choice +

1 choice in
same genus) | | |
| | 300 | 91.7%
825/900 | 4.4%
40/900 | 96.1%
865/900 | 0.2%
2/900 | 3.7%
33/900 |

Prospective Clinical Study:

The following performance characteristics were obtained by testing from patient cultures, including Gram-positive bacteria, Gram- negative bacteria and yeasts, in five clinical microbiology laboratories in the United States, comparing VITEK®MS identification to a reference identification determined by molecular sequencing supplemented as needed by additional molecular sequencing and/or biochemical testing.

14

Correction Identification (ID)
Organism
Group	Correct
Single
Choice
(no. results)	Low
Discrim.*
Correct
Genus
(no. results)	Combined Correct
Single Choice and Low
Discrim. Correct Genus
(no. results)	Single
Choice
Incorrect
ID (no.
results)1	Low
Discrim.
Incorrect
Genus
(no.
results)	Low
Discrim.
Multiple
Genera
(no. results)	No ID2
(no. results)
Gram-
positive
bacteria	89.5%
(2020/2256)	4.0%
(90/2256)	93.5% (2110/2256)
95% CI [92.4 ; 94.5]%	0.6%
(13/2256)	0.04%
(1/2256)	2.1%
(48/2256)	3.7% (84/2256)
Gram-
negative
bacteria	83.8%
(3062/3656)	9.0%
(329/3656)	92.8% (3391/3656)
95% CI [91.9 ; 93.6]%	1.1%
(39/3656)	0.3%
(11/3656)	2.8%
(104/3656)	3.0% (111/3656)
Yeasts	95.3%
(1102/1156)	1.0%
(11/1156)	96.3% (1113/1156)
95% CI [95.0 ; 97.3]%	0.2%
(2/1156)	0.0%
(0/1156)	0.6%
(7/1156)	2.9% (34/1156)
Total	87.5%
(6184/7068)	6.1%
(430/7068)	93.6% (6614/7068)
95% CI [93.0 ; 94.1]%	0.8%
(54/7068)	0.2%
(12/7068)	2.2%
(159/7068)	3.2% (229/7068)

Key:

• 1 = A table of single choice incorrect identifications is included after the Performance Characteristics by Species table.
• 2 = Includes No ID (i.e. Bad Spectra, Not Enough Peaks, Too Many Peaks (Bad spectrum), or No ID (Good spectrum).
• 3 = Of the 430 low discrimination same genus results, 426 (99.1%) had the correct species present and 4 (0.9%) did not have the correct species present.
• 4 = Of the 159 low discrimination multiple genera results, 140 (88.0%) had the correct species present and 19 (12.0%) did not have the correct species present.

15

| Species | Number
of
isolates | Correct Identification (ID) | Discordant1 | No identification2 | | |
|--------------------------------------------------|--------------------------|-------------------------------------------------|----------------------------------------------|---------------------------------------------------------|-----------|-------------|
| | | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +

1 choice in same
genus) | | |
| Abiotrophia defective | 9 | 96.9% 31/32 | 0% 0/32 | 96.9% 31/32 | 0% 0/32 | 3.1% 1/32 |
| Achromobacter denitrificans 3 | 17 | 0% 0/37 | 91.9% 34/37 | 91.9% 34/37 | 0% 0/37 | 8.1% 3/37 |
| Achromobacter xylosoxidans 3 | 24 | 0% 0/24 | 91.7% 22/24 | 91.7% 22/24 | 0% 0/24 | 8.3% 2/24 |
| Acinetobacter baumannii
complex | 65 | 87.9% 80/91 | 0% 0/91 | 87.9% 80/91 | 0% 0/91 | 12.1% 11/91 |
| Acinetobacter haemolyticus | 6 | 93.3% 28/30 | 3.3% 1/30 | 96.7% 29/30 | 0% 0/30 | 3.3% 1/30 |
| Acinetobacter junii | 11 | 50.0% 14/28 | 17.9% 5/28 | 67.9% 19/28 | 7.1% 2/28 | 25.0% 7/28 |
| Acinetobacter lwoffii | 26 | 84.6% 22/26 | 3.8% 1/26 | 88.5% 23/26 | 0% 0/26 | 11.5% 3/26 |
| Actinomyces meyeri | 8 | 70.0% 21/30 | 6.7% 2/30 | 76.7% 23/30 | 6.7% 2/30 | 16.7% 5/30 |
| Actinomyces neuii | 12 | 64.7% 33/51 | 0% 0/51 | 64.7% 33/51 | 2.0% 1/51 | 33.3% 17/51 |
| Actinomyces odontolyticus | 7 | 68.8% 22/32 | 9.4% 3/32 | 78.1% 25/32 | 0% 0/32 | 21.9% 7/32 |
| Aerococcus viridans | 15 | 97.2% 35/36 | 0% 0/36 | 97.2% 35/36 | 0% 0/36 | 2.8% 1/36 |
| Aeromonas hydrophila/caviae 4 | 25 | 64.0% 16/25 | 24.0% 6/25 | 88.0% 22/25 | 8.0% 2/25 | 4.0% 1/25 |
| Aeromonas sobria 4 | 10 | 37.9% 11/29 | 51.7% 15/29 | 89.7% 26/29 | 3.4% 1/29 | 6.9% 2/29 |
| Aggregatibacter
actinomycetemcomitans | 7 | 83.9% 26/31 | 0% 0/31 | 83.9% 26/31 | 6.5% 2/31 | 9.7% 3/31 |
| Aggregatibacter aphrophilus | 6 | 83.9% 26/31 | 0% 0/31 | 83.9% 26/31 | 0% 0/31 | 16.1% 5/31 |
| Aggregatibacter segnis | 4 | 63.3% 19/30 | 6.7% 2/30 | 70.0% 21/30 | 0% 0/30 | 30.0% 9/30 |
| Alcaligenes faecalis ssp faecalis | 12 | 97.1% 33/34 | 0% 0/34 | 97.1% 33/34 | 2.9% 1/34 | 0% 0/34 |
| Bacteroides caccae | 30 | 95.9% 47/49 | 2.0% 1/49 | 98.0% 48/49 | 0% 0/49 | 2.0% 1/49 |
| Bacteroides fragilis | 71 | 98.6% 70/71 | 0.0% 0/71 | 98.6% 70/71 | 0% 0/71 | 1.4% 1/71 |

16

| Species | Number of
isolates | Correct Identification (ID) | | | | | | Discordant 1 | | No identification2 | |
|------------------------------|-----------------------|-------------------------------------------------|-------|----------------------------------------------|------|---------------------------------------------------------|-------|--------------|------|--------------------|-------|
| | | Correct for
Genus &
Species
(1 choice) | | Low Discrim.
(>1 choice in
same genus) | | Combined
(1 choice +

1 choice in same
genus) | | | | | |
| Bacteroides ovatus | 40 | 85.0% | 34/40 | 2.5% | 1/40 | 87.5% | 35/40 | 0% | 0/40 | 12.5% | 5/40 |
| Bacteroides thetaiotaomicron | 51 | 94.1% | 48/51 | 2.0% | 1/51 | 96.1% | 49/51 | 0% | 0/51 | 3.9% | 2/51 |
| Bacteroides uniformis | 30 | 80.4% | 41/51 | 0% | 0/51 | 80.4% | 41/51 | 0% | 0/51 | 19.6% | 10/51 |
| Bacteroides vulgatus | 41 | 97.6% | 40/41 | 0% | 0/41 | 97.6% | 40/41 | 0% | 0/41 | 2.4% | 1/41 |
| Bordetella parapertussis | 6 | 96.7% | 29/30 | 3.3% | 1/30 | 100% | 30/30 | 0% | 0/30 | 0% | 0/30 |
| Bordetella pertussis | 9 | 46.7% | 14/30 | 26.7% | 8/30 | 73.3% | 22/30 | 3.3% | 1/30 | 23.3% | 7/30 |
| Brevundimonas diminuta | 7 | 93.3% | 28/30 | 0% | 0/30 | 93.3% | 28/30 | 0% | 0/30 | 6.7% | 2/30 |
| Burkholderia multivorans | 25 | 91.3% | 42/46 | 4.3% | 2/46 | 95.7% | 44/46 | 2.2% | 1/46 | 2.2% | 1/46 |
| Campylobacter coli | 12 | 96.9% | 31/32 | 0% | 0/32 | 96.9% | 31/32 | 3.1% | 1/32 | 0% | 0/32 |
| Campylobacter jejuni | 33 | 93.9% | 31/33 | 0% | 0/33 | 93.9% | 31/33 | 3.0% | 1/33 | 3.0% | 1/33 |
| Candida albicans | 58 | 98.3% | 57/58 | 0% | 0/58 | 98.3% | 57/58 | 1.7% | 1/58 | 0% | 0/58 |
| Candida dubliniensis | 34 | 100% | 34/34 | 0% | 0/34 | 100% | 34/34 | 0% | 0/34 | 0% | 0/34 |
| Candida famata | 29 | 91.8% | 45/49 | 6.1% | 3/49 | 98.0% | 48/49 | 0% | 0/49 | 2.0% | 1/49 |
| Candida glabrata | 62 | 100% | 62/62 | 0% | 0/62 | 100% | 62/62 | 0% | 0/62 | 0% | 0/62 |
| Candida guilliermondii | 36 | 97.2% | 35/36 | 0% | 0/36 | 97.2% | 35/36 | 0% | 0/36 | 2.8% | 1/36 |
| Candida haemulonii | 12 | 100% | 34/34 | 0% | 0/34 | 100% | 34/34 | 0% | 0/34 | 0% | 0/34 |
| Candida inconspicua | 23 | 93.0% | 40/43 | 2.3% | 1/43 | 95.3% | 41/43 | 0% | 0/43 | 4.7% | 2/43 |
| Candida intermedia | 7 | 92.6% | 25/27 | 3.7% | 1/27 | 96.3% | 26/27 | 0% | 0/27 | 3.7% | 1/27 |
| Candida kefyr | 30 | 100% | 30/30 | 0% | 0/30 | 100% | 30/30 | 0% | 0/30 | 0% | 0/30 |

17

| Species | Number
of
isolates | Correct Identification (ID) | | Discordant1 | No identification2 | | |
|--------------------------------|--------------------------|-------------------------------------------------|----------------------------------------------|---------------------------------------------------------|--------------------|-------------|--------------------|
| | | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +

1 choice in same
genus) | | | |
| Candida krusei | 53 | 100% | 0% | 100% | 0% | 0% | |
| Candida lambica | 9 | 96.8% | 3.2% | 100% | 0% | 0% | |
| Candida lipolytica | 28 | 100% | 0% | 100% | 0% | 0% | |
| Candida lusitaniae | 33 | 87.9% | 3.0% | 90.9% | 0% | 9.1% | |
| Candida norvegensis | 30 | 90.0% | 2.0% | 92.0% | 0% | 8.0% | |
| Candida parapsilosis | 73 | 98.6% | 0% | 98.6% | 1.4% | 0% | |
| Candida pelliculosa | 33 | 100% | 0% | 100% | 0% | 0% | |
| Candida rugosa | 6 | 100% | 0% | 100% | 0% | 0% | |
| Candida tropicalis | 54 | 90.7% | 3.7% | 94.4% | 0% | 5.6% | |
| Candida utilis | 8 | 96.7% | 0% | 96.7% | 0% | 3.3% | |
| Candida zeylanoides | 8 | 96.7% | 3.3% | 100% | 0% | 0% | |
| Chryseobacterium indologenes | 8 | 87.9% | 0% | 87.9% | 0% | 12.1% | |
| Citrobacter amalonaticus | 29 | 93.1% | 3.4% | 96.6% | 0% | 3.4% | |
| Citrobacter braakii5 | 18 | 56.4% | 30.8% | 87 2% | 5.1% | 7.7% | |
| Citrobacter freundii5 | 58 | 65.5% | 27.6% | 93.1% | 6 9% | 0% | |
| Citrobacter koseri | 31 | 100% | 0% | 100% | 0% | 0% | |
| Citrobacter youngae5 | 13 | 44.1% | 52 9% | 97.1% | 0% | 2 9% | |
| Clostridium clostridioforme | 7 | 91.7% | 0% | 91.7% | 8 3% | 0% | |
| Clostridium difficile | 30 | 90.0% | 0% | 90.0% | 0% | 10.0% | |
| Species | Number
of
isolates | Correct Identification (ID) | | | | Discordant1 | No identification2 |
| | | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +
1 choice in same
genus) | | | |
| Clostridium perfringens | 61 | 98.4% | 0% | 98.4% | 0% 0/61 | 1.6% 1/61 | |
| Clostridium ramosum | 10 | 90.3% | 0% | 90.3% | 3.2% 1/31 | 6.5% 2/31 | |
| Corynebacterium jeikeium | 8 | 100% | 0% | 100% | 0% 0/31 | 0% 0/31 | |
| Cronobacter sakazakii | 10 | 73.3% | 26.7% | 100% | 0% 0/30 | 0% 0/30 | |
| Cryptococcus neoformans | 35 | 100% | 0% | 100% | 0% 0/35 | 0% 0/35 | |
| Edwardsiella hoshinae | 11 | 93.9% | 6.1% | 100% | 0% 0/33 | 0% 0/33 | |
| Edwardsiella tarda | 9 | 93.1% | 6.9% | 100% | 0% 0/29 | 0% 0/29 | |
| Eikenella corrodens | 14 | 100% | 0% | 100% | 0% 0/34 | 0% 0/34 | |
| Elizabethkingia meningoseptica | 10 | 100% | 0% | 100% | 0% 0/32 | 0% 0/32 | |
| Enterobacter aerogenes | 52 | 100% | 0% | 100% | 0% 0/52 | 0% 0/52 | |
| Enterobacter asburiae6 | 12 | 0% | 87.9% | 87.9% | 0% 0/33 | 12.1% 4/33 | |
| Enterobacter cancerogenus | 6 | 61.3% | 29.0% | 90.3% | 3.2% 1/31 | 6.5% 2/31 | |
| Enterobacter cloacae6 | 28 | 0% | 92.9% | 92.9% | 3.6% 1/28 | 3.6% 1/28 | |
| Enterobacter gergoviae | 10 | 90.6% | 0% | 90.6% | 3.1% 1/32 | 6.3% 2/32 | |
| Enterococcus avium | 33 | 90.9% | 3.0% | 93.9% | 0% 0/33 | 6.1% 2/33 | |
| Enterococcus casseliflavus | 37 | 100% | 0% | 100% | 0% 0/37 | 0% 0/37 | |
| Enterococcus durans | 30 | 96.7% | 0% | 96.7% | 3.3% 1/30 | 0% 0/30 | |
| Enterococcus faecalis | 68 | 97.1% | 0% | 97.1% | 0% 0/68 | 2.9% 2/68 | |
| Enterococcus faecium | 57 | 100% | 0% | 100% | 0% 0/57 | 0% 0/57 | |

18

19

| Species | Number
of
isolates | Correct for
Genus &
Species
(1 choice) | | Low Discrim.
(>1 choice in
same genus) | | Combined
(1 choice +

1 choice in same
genus) | Discordant¹ | | No identification² | | |
|------------------------------|--------------------------|-------------------------------------------------|-------|----------------------------------------------|-------|---------------------------------------------------------|-------------|------|--------------------|-------|------|
| Enterococcus gallinarum | 34 | 100% | 34/34 | 0% | 0/34 | 100% | 34/34 | 0% | 0/34 | 0% | 0/34 |
| Escherichia coli | 65 | 100% | 65/65 | 0% | 0/65 | 100% | 65/65 | 0% | 0/65 | 0% | 0/65 |
| Escherichia fergusonii | 6 | 48.1% | 13/27 | 22.2% | 6/27 | 70.4% | 19/27 | 7.4% | 2/27 | 22.2% | 6/27 |
| Escherichia hermannii | 7 | 78.1% | 25/32 | 0% | 0/32 | 78.1% | 25/32 | 3.1% | 1/32 | 18.8% | 6/32 |
| Ewingella americana | 6 | 90.0% | 27/30 | 0% | 0/30 | 90.0% | 27/30 | 3.3% | 1/30 | 6.7% | 2/30 |
| Finegoldia magna | 24 | 97.7% | 43/44 | 0% | 0/44 | 97.7% | 43/44 | 0% | 0/44 | 2.3% | 1/44 |
| Fusobacterium necrophorum | 26 | 88.9% | 40/45 | 0% | 0/45 | 88.9% | 40/45 | 0% | 0/45 | 11.1% | 5/45 |
| Fusobacterium nucleatum | 7 | 59.1% | 13/22 | 4.5% | 1/22 | 63.6% | 14/22 | 9.1% | 2/22 | 27.3% | 6/22 |
| Gardnerella vaginalis | 27 | 88.4% | 38/43 | 0% | 0/43 | 88.4% | 38/43 | 0% | 0/43 | 11.6% | 5/43 |
| Gemella haemolysans | 11 | 78.8% | 26/33 | 18.2% | 6/33 | 97.0% | 32/33 | 0% | 0/33 | 3.0% | 1/33 |
| Gemella morbillorum | 5 | 46.7% | 14/30 | 40.0% | 12/30 | 86.7% | 26/30 | 0% | 0/30 | 13.3% | 4/30 |
| Geotrichum capitatum | 32 | 93.8% | 30/32 | 0% | 0/32 | 93.8% | 30/32 | 0% | 0/32 | 6.3% | 2/32 |
| Granulicatella adiacens | 6 | 100% | 31/31 | 0% | 0/31 | 100% | 31/31 | 0% | 0/31 | 0% | 0/31 |
| Haemophilus influenzae | 55 | 96.4% | 53/55 | 0% | 0/55 | 96.4% | 53/55 | 0% | 0/55 | 3.6% | 2/55 |
| Haemophilus parahaemolyticus | 8 | 100% | 31/31 | 0% | 0/31 | 100% | 31/31 | 0% | 0/31 | 0% | 0/31 |
| Haemophilus parainfluenzae | 37 | 91.9% | 34/37 | 2.7% | 1/37 | 94.6% | 35/37 | 0% | 0/37 | 5.4% | 2/37 |
| Hafnia alvei | 19 | 84.2% | 16/19 | 0% | 0/19 | 84.2% | 16/19 | 5.3% | 1/19 | 10.5% | 2/19 |
| Kingella denitrificans | 3 | 95.8% | 23/24 | 0% | 0/24 | 95.8% | 23/24 | 0% | 0/24 | 4.2% | 1/24 |
| Kingella kingae | 4 | 83.3% | 25/30 | 0% | 0/30 | 83.3% | 25/30 | 0% | 0/30 | 16.7% | 5/30 |

20

| Species | Number
of
isolates | Correct Identification (ID) | | | Discordant1 | No identification2 |
|----------------------------------------------------------------------------------------|--------------------------|-------------------------------------------------|----------------------------------------------|---------------------------------------------------------|--------------------|--------------------|
| | | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +

1 choice in same
genus) | | |
| Klebsiella oxytoca | 49 | 100% 49/49 | 0% 0/49 | 100% 49/49 | 0% 0/49 | 0% 0/49 |
| Klebsiella pneumoniae | 58 | 100% 58/58 | 0% 0/58 | 100% 58/58 | 0% 0/58 | 0% 0/58 |
| Kodamaea ohmeri | 11 | 93.5% 29/31 | 0% 0/31 | 93.5% 29/31 | 0% 0/31 | 6.5% 2/31 |
| Lactococcus garvieae | 9 | 100% 31/31 | 0% 0/31 | 100% 31/31 | 0% 0/31 | 0% 0/31 |
| Lactococcus lactis ssp lactis | 10 | 93.5% 29/31 | 3.2% 1/31 | 96.8% 30/31 | 0% 0/31 | 3.2% 1/31 |
| Leclercia adecarboxylata | 10 | 93.5% 29/31 | 0% 0/31 | 93.5% 29/31 | 0% 0/31 | 6.5% 2/31 |
| Legionella pneumophila | 26 | 96.1% 49/51 | 0% 0/51 | 96.1% 49/51 | 0% 0/51 | 3.9% 2/51 |
| Leuconostoc mesenteroides | 11 | 93.5% 29/31 | 0% 0/31 | 93.5% 29/31 | 0% 0/31 | 6.5% 2/31 |
| Leuconostoc
pseudomesenteroides | 5 | 76.0% 19/25 | 0% 0/25 | 76.0% 19/25 | 0% 0/25 | 24.0% 6/25 |
| Listeria monocytogenes | 45 | 75.6% 34/45 | 8.9% 4/45 | 84.4% 38/45 | 0% 0/45 | 15.6% 7/45 |
| Malassezia furfur | 7 | 94.6% 35/37 | 0% 0/37 | 94.6% 35/37 | 0% 0/37 | 5.4% 2/37 |
| Malassezia pachydermatis | 8 | 46.4% 13/28 | 0% 0/28 | 46.4% 13/28 | 0% 0/28 | 53.6% 15/28 |
| Micrococcus luteus/lylae | 35 | 94.3% 33/35 | 0% 0/35 | 94.3% 33/35 | 0% 0/35 | 5.7% 2/35 |
| Mobiluncus curtisii | 4 | 86.2% 25/29 | 0% 0/29 | 86.2% 25/29 | 0% 0/29 | 13.8% 4/29 |
| Moraxella (Branhamella)
catarrhalis | 33 | 100% 33/33 | 0% 0/33 | 100% 33/33 | 0% 0/33 | 0% 0/33 |
| Morganella morganii | 52 | 100% 52/52 | 0% 0/52 | 100% 52/52 | 0% 0/52 | 0% 0/52 |
| Neisseria cinerea | 9 | 90.6% 29/32 | 3.1% 1/32 | 93.8% 30/32 | 0% 0/32 | 6.3% 2/32 |
| Neisseria gonorrhoeae8 | 29 | 89.7% 26/29 | 3.4% 1/29 | 93.1% 27/29 | 0% 0/29 | 6.9% 2/29 |
| Neisseria meningitidis | 9 | 96.9% 31/32 | 0% 0/32 | 96.9% 31/32 | 0% 0/32 | 3.1% 1/32 |
| Species | Number
of
isolates | Correct Identification (ID) | | | Discordant¹ | No identification² |
| | | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +
1 choice in same
genus) | | |
| Neisseria mucosa | 9 | 63.3% 19/30 | 23.3% 7/30 | 86.7% 26/30 | 0% 0/30 | 13.3% 4/30 |
| Ochrobactrum anthropi | 10 | 90.3% 28/31 | 0% 0/31 | 90.3% 28/31 | 3.2% 1/31 | 6.5% 2/31 |
| Oligella ureolytica | 9 | 86.7% 26/30 | 0% 0/30 | 86.7% 26/30 | 0% 0/30 | 13.3% 4/30 |
| Oligella urethralis | 14 | 88.2% 30/34 | 0% 0/34 | 88.2% 30/34 | 2.9% 1/34 | 8.8% 3/34 |
| Pantoea agglomerans | 22 | 86.4% 19/22 | 0% 0/22 | 86.4% 19/22 | 13.6% 3/22 | 0% 0/22 |
| Parvimonas micra | 10 | 85.3% 29/34 | 0% 0/34 | 85.3% 29/34 | 0% 0/34 | 14.7% 5/34 |
| Pasteurella multocida | 14 | 100% 36/36 | 0% 0/36 | 100% 36/36 | 0% 0/36 | 0% 0/36 |
| Pediococcus acidilactici | 7 | 92.6% 25/27 | 0% 0/27 | 92.6% 25/27 | 0% 0/27 | 7.4% 2/27 |
| Peptoniphilus asaccharolyticus | 4 | 100% 14/14 | 0% 0/14 | 100% 14/14 | 0% 0/14 | 0% 0/14 |
| Peptostreptococcus anaerobius | 36 | 94.6% 53/56 | 0% 0/56 | 94.6% 53/56 | 1.8% 1/56 | 3.6% 2/56 |
| Prevotella bivia | 34 | 100.0% 34/34 | 0% 0/34 | 100% 34/34 | 0% 0/34 | 0% 0/34 |
| Prevotella buccae | 23 | 93.8% 45/48 | 0% 0/48 | 93.8% 45/48 | 0% 0/48 | 6.3% 3/48 |
| Prevotella denticola | 6 | 93.5% 29/31 | 0% 0/31 | 93.5% 29/31 | 0% 0/31 | 6.5% 2/31 |
| Prevotella intermedia | 16 | 85.2% 23/27 | 3.7% 1/27 | 88.9% 24/27 | 0% 0/27 | 11.1% 3/27 |
| Prevotella melaninogenica | 11 | 61.5% 16/26 | 7.7% 2/26 | 69.2% 18/26 | 7.7% 2/26 | 23.1% 6/26 |
| Propionibacterium acnes | 52 | 82.7% 43/52 | 1.9% 1/52 | 84.6% 44/52 | 0% 0/52 | 15.4% 8/52 |
| Proteus mirabilis | 58 | 98.3% 57/58 | 0% 0/58 | 98.3% 57/58 | 0% 0/58 | 1.7% 1/58 |
| Proteus penneri⁹ | 19 | 0% 0/39 | 97.4% 38/39 | 97.4% 38/39 | 0% 0/39 | 2.6% 1/39 |
| Proteus vulgaris⁹ | 23 | 0% 0/23 | 100% 23/23 | 100% 23/23 | 0% 0/23 | 0% 0/23 |
| Species | Number of isolates | Correct Identification (ID) | | | Discordant¹ | No identification² |
| | | Correct for Genus & Species (1 choice) | Low Discrim. (>1 choice in same genus) | Combined (1 choice + > 1 choice in same genus) | | |
| Providencia rettgeri | 33 | 97.0% 32/33 | 0% 0/33 | 97.0% 32/33 | 0% 0/33 | 3.0% 1/33 |
| Providencia stuartii | 31 | 100% 31/31 | 0% 0/31 | 100% 31/31 | 0% 0/31 | 0% 0/31 |
| Pseudomonas aeruginosa | 57 | 96.5% 55/57 | 0% 0/57 | 96.5% 55/57 | 0% 0/57 | 3.5% 2/57 |
| Pseudomonas fluorescens | 19 | 78.9% 15/19 | 15.8% 3/19 | 94.7% 18/19 | 0% 0/19 | 5.3% 1/19 |
| Pseudomonas putida | 25 | 80.0% 20/25 | 4.0% 1/25 | 84.0% 21/25 | 4.0% 1/25 | 12.0% 3/25 |
| Pseudomonas stutzeri | 8 | 87.9% 29/33 | 0% 0/33 | 87.9% 29/33 | 6.1% 2/33 | 6.1% 2/33 |
| Ralstonia pickettii | 10 | 70.4% 19/27 | 0% 0/27 | 70.4% 19/27 | 3.7% 1/27 | 25.9% 7/27 |
| Raoultella ornithinolytica | 11 | 90.6% 29/32 | 3.1% 1/32 | 93.8% 30/32 | 3.1% 1/32 | 3.1% 1/32 |
| Raoultella planticola | 9 | 80.6% 25/31 | 0% 0/31 | 80.6% 25/31 | 3.2% 1/31 | 16.1% 5/31 |
| Rhizobium radiobacter | 14 | 81.8% 27/33 | 0% 0/33 | 81.8% 27/33 | 9.1% 3/33 | 9.1% 3/33 |
| Rhodotorula mucilaginosa | 35 | 100% 35/35 | 0% 0/35 | 100% 35/35 | 0% 0/35 | 0% 0/35 |
| Rothia mucilaginosa | 8 | 50.0% 16/32 | 3.1% 1/32 | 53.1% 17/32 | 0% 0/32 | 46.9% 15/32 |
| Saccharomyces cerevisiae | 42 | 97.6% 41/42 | 0% 0/42 | 97.6% 41/42 | 0% 0/42 | 2.4% 1/42 |
| Salmonella group⁸ | 35 | 94.3% 33/35 | 5.7% 2/35 | 100% 35/35 | 0% 0/35 | 0% 0/35 |
| Serratia fonticola | 7 | 66.7% 20/30 | 23.3% 7/30 | 90.0% 27/30 | 3.3% 1/30 | 6.7% 2/30 |
| Serratia liquefaciens | 23 | 95.7% 22/23 | 4.3% 1/23 | 100% 23/23 | 0% 0/23 | 0% 0/23 |
| Serratia marcescens | 57 | 100% 57/57 | 0% 0/57 | 100% 57/57 | 0% 0/57 | 0% 0/57 |
| Serratia odorifera | 30 | 100% 30/30 | 0% 0/30 | 100% 30/30 | 0% 0/30 | 0% 0/30 |
| Sphingobacterium multivorum | 5 | 86.2% 25/29 | 0% 0/29 | 86.2% 25/29 | 3.4% 1/29 | 10.3% 3/29 |
| Species | Number
of
isolates | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +
1 choice in same
genus) | Discordant¹ | No identification² |
| Sphingobacterium spiritivorum | 10 | 96.7% | 0% 0/30 | 96.7% | 3.3% 1/30 | 0% 0/30 |
| Sphingomonas paucimobilis | 9 | 96.8% | 0% 0/31 | 96.8% | 0% 0/31 | 3.2% 1/31 |
| Staphylococcus aureus | 61 | 98.4% | 0% 0/61 | 98.4% | 0% 0/61 | 1.6% 1/61 |
| Staphylococcus capitis | 34 | 94.1% | 0% 0/34 | 94.1% | 2.9% 1/34 | 2.9% 1/34 |
| Staphylococcus cohnii ssp cohnii | 8 | 93.3% | 6.7% 2/30 | 100% | 0% 0/30 | 0% 0/30 |
| Staphylococcus cohnii ssp
urealyticus | 12 | 96.8% | 0% 0/31 | 96.8% | 0% 0/31 | 3.2% 1/31 |
| Staphylococcus epidermidis | 88 | 97.7% | 0% 0/88 | 97.7% | 2.3% 2/88 | 0% 0/88 |
| Staphylococcus haemolyticus | 38 | 100% | 0% 0/38 | 100% | 0% 0/38 | 0% 0/38 |
| Staphylococcus hominis ssp
hominis | 21 | 100% | 0% 0/21 | 100% | 0% 0/21 | 0% 0/21 |
| Staphylococcus lugdunensis | 33 | 100% | 0% 0/33 | 100% | 0% 0/33 | 0% 0/33 |
| Staphylococcus saprophyticus | 35 | 91.4% | 0% 0/35 | 91.4% | 0% 0/35 | 8.6% 3/35 |
| Staphylococcus schleiferi | 7 | 100% | 0% 0/32 | 100% | 0% 0/32 | 0% 0/32 |
| Staphylococcus sciuri | 7 | 93.3% | 3.3% 1/30 | 96.7% | 0% 0/30 | 3.3% 1/30 |
| Staphylococcus simulans | 31 | 100% | 0% 0/31 | 100% | 0% 0/31 | 0% 0/31 |
| Staphylococcus warneri | 33 | 84.8% | 0% 0/33 | 84.8% | 3.0% 1/33 | 12.1% 4/33 |
| Stenotrophomonas maltophilia | 53 | 96.2% | 0% 0/53 | 96.2% | 1.9% 1/53 | 1.9% 1/53 |
| Streptococcus agalactiae | 58 | 100% | 0% 0/58 | 100% | 0% 0/58 | 0% 0/58 |
| Streptococcus anginosus | 47 | 95.7% | 0% 0/47 | 95.7% | 0% 0/47 | 4.3% 2/47 |
| Streptococcus constellatus | 30 | 86.7% | 6.7% 2/30 | 93.3% | 0% 0/30 | 6.7% 2/30 |
| Species | Number of isolates | Correct Identification (ID) | | Discordant¹ | No identification² | |
| | | Correct for Genus & Species (1 choice) | Low Discrim. (>1 choice in same genus) | | | |
| Streptococcus dysgalactiae ssp equisimilis/Streptococcus dysgalactiae ssp dysgalactiae | 47 | 0% 0/47 | 93.6% 44/47 | 0% 0/47 | 6.4% 3/47 | |
| Streptococcus gallolyticus ssp gallolyticus | 5 | 100% 30/30 | 0% 0/30 | 0% 0/30 | 0% 0/30 | |
| Streptococcus infantarius ssp coli (Str.lutetiensis) | 9 | 100% 31/31 | 0% 0/31 | 0% 0/31 | 0% 0/31 | |
| Streptococcus infantarius ssp infantarius | 12 | 94.1% 32/34 | 2.9% 1/34 | 0% 0/34 | 2.9% 1/34 | |
| Streptococcus intermedius | 20 | 88.4% 38/43 | 11.6% 5/43 | 0% 0/43 | 0% 0/43 | |
| Streptococcus mitis/Streptococcus oralis | 37 | 86.5% 32/37 | 2.7% 1/37 | 0% 0/37 | 10.8% 4/37 | |
| Streptococcus mutans | 9 | 87.1% 27/31 | 6.5% 2/31 | 0% 0/31 | 6.5% 2/31 | |
| Streptococcus pneumoniae | 51 | 96.1% 49/51 | 0% 0/51 | 0% 0/51 | 3.9% 2/51 | |
| Streptococcus pyogenes | 55 | 96.4% 53/55 | 0% 0/55 | 0% 0/55 | 3.6% 2/55 | |
| Streptococcus salivarius ssp salivarius | 8 | 93.8% 30/32 | 3.1% 1/32 | 0% 0/32 | 3.1% 1/32 | |
| Streptococcus sanguinis | 34 | 91.2% 31/34 | 0% 0/34 | 8.8% 3/34 | 0.0% 0/34 | |
| Trichosporon asahii | 32 | 93.8% 30/32 | 0% 0/32 | 0% 0/32 | 6.3% 2/32 | |
| Trichosporon inkin | 9 | 100% 30/30 | 0% 0/30 | 0% 0/30 | 0% 0/30 | |
| Trichosporon mucoides | 9 | 97.1% 33/34 | 0% 0/34 | 0% 0/34 | 2.9% 1/34 | |
| Vibrio cholerae | 11 | 90.9% 30/33 | 3.0% 1/33 | 3.0% 1/33 | 3.0% 1/33 | |
| Vibrio parahaemolyticus | 16 | 94.4% 34/36 | 2.8% 1/36 | 0% 0/36 | 2.8% 1/36 | |
| Vibrio vulnificus | 11 | 93.9% 31/33 | 0% 0/33 | 0% 0/33 | 6.1% 2/33 | |
| Yersinia enterocolitica | 14 | 100% 35/35 | 0% 0/35 | 0% 0/35 | 0% 0/35 | |
| Species | Number
of
isolates | Correct Identification (ID) | | | Discordant1 | No identification2 |
| | | Correct for
Genus &
Species
(1 choice) | Low Discrim.
(>1 choice in
same genus) | Combined
(1 choice +
1 choice in same
genus) | | |
| Yersinia frederiksenii | 10 | 80.0% 24/30 | 6.7% 2/30 | 86.7% 26/30 | 3.3% 1/30 | 10.0% 3/30 |
| Yersinia intermedia | 9 | 90.0% 27/30 | 10.0% 3/30 | 100% 30/30 | 0% 0/30 | 0% 0/30 |
| Yersinia kristensenii | 7 | 90.0% 27/30 | 6.7% 2/30 | 96.7% 29/30 | 0% 0/30 | 3.3% 1/30 |
| Yersinia pseudotuberculosis | 8 | 96.7% 29/30 | 3.3% 1/30 | 100% 30/30 | 0% 0/30 | 0% 0/30 |

21

22

23

24

25

*Discrim. = Discrimination

• 1 = Includes single choice incorrect identifications and low discrimination results with >1 choice in same genus but genus does not match the reference genus.
• 2 = Includes Low Discrimination with multiple genera or No ID (i.e. Bad Spectra, Not Enough Peaks, Too Many Peaks (Bad spectrum), or No ID (Good spectrum).
• 3 = Achromobacter denitrificans and Achromobacter xylosoxidans identifications should be considered as a slashline result, Achromobacter denitrificans/ Achromobacter xylosoxidans.
• 4 = Aeromonas hydrophila/caviae and Aeromonas sobria should be considered as an Aeromonas species group identification.
• 5 = Citrobacter freundii. Citrobacter braakii and Citrobacter youngae should be considered as Citrobacter freundii complex.
• 6 = Enterobacter cloacae and Enterobacter asburiae identifications should be considered as a slashline result, Enterobacter cloacae/ Enterobacter asburiae.
• 7 = Shigella species and E. coli 0157 are identified as Escherichia coli. Confirmatory tests are required to differentiate Escherichia coli from Shigella species or E. coli 0157.
• 8 = Confirmatory tests are recommended for Neisseria gonorrhoeae; Salmonella: confirm by serological tests.
• 9 = Proteus penneri and Proteus vulgaris identifications should be considered as a slashline result, Proteus penneri/ Proteus vulgaris.

26

Single Choice Discordant Results

No.	Reference Result	VITEK® MS Result	No.	Reference Result	VITEK® MS Result
2	Acinetobacter junii	Acinetobacter
haemolyticus	2	Escherichia
fergusonii	Escherichia coli
2	Actinomyces meyeri	Actinomyces
odontolyticus	1	Escherichia
hermannii	Citrobacter koseri
1	Actinomyces neuii ssp
neuii	Bacteroides
vulgatus	1	Ewingella
americana	Enterobacter
gergoviae
2	Aeromonas caviae	Aeromonas sobria	1	Hafnia alvei	Obesumbacterium
proteus*
1	Aeromonas sobria	Aggregatibacter
hydrophila/caviae	1	Ochrobactrum
anthropi	Corynebacterium
striatum*
1	Aggregatibacter
actinomycetemcomitans	Aggregatibacter
aphrophilus	2	Pantoea
agglomerans	Enterobacter
cancerogenus
1	Aggregatibacter
actinomycetemcomitans	Sphingobacterium
spiritivorum	1	Peptostreptococcus
anaerobius	Clostridium
sordellii*
1	Alcaligenes faecalis ssp
faecalis	Staphylococcus
aureus	1	Prevotella
melaninogenica	Micrococcus
luteus/lylae
1	Bordetella pertussis	Bordetella
parapertussis	1	Pseudomonas
putida	Pseudomonas
viridiflava*
1	Burkholderia
multivorans	Yersinia ruckeri*	1	Pseudomonas
stutzeri	Moraxella
(Branhamella)
catarrhalis
1	Campylobacter coli	Campylobacter
jejuni	1	Raoultella
ornithinolytica	Enterobacter
aerogenes
1	Campylobacter jejuni	Campylobacter
coli	1	Raoultella
planticola	Raoultella
ornithinolytica
1	Candida albicans	Candida
dubliniensis	1	Rhizobium
radiobacter	Obesumbacterium
proteus*
1	Candida parapsilosis	Candida
pelliculosa	1	Serratia fonticola	Serratia
liquefaciens
1	Citrobacter braakii	Citrobacter
freundii	1	Sphingobacterium
multivorum	Myroides spp*
1	Citrobacter braakii	Citrobacter
youngae	1	Staphylococcus
epidermidis	Staphylococcus
hominis
ssp hominis
2	Citrobacter freundii	Citrobacter
werkmanii	1	Staphylococcus
epidermidis	Staphylococcus
caprae*
2	Citrobacter freundii	Citrobacter
youngae	1	Staphylococcus
warneri	Staphylococcus
pasteuri*
1	Clostridium
clostridioforme	Clostridium
bifermentans*	1	Streptococcus
maltophilia	Ochrobactrum
anthropi
1	Clostridium ramosum	Propionibacterium
propionicum	2	Streptococcus
sanguinis	Streptococcus
mitis/oralis
1	Enterobacter
cancerogenus	Klebsiella oxytoca	1	Streptococcus
sanguinis	Streptococcus
anginosus
1	Enterobacter gergoviae	Enterobacter
aerogenes	1	Vibrio cholerae	Vibrio
parahaemolyticus
1	Enterococcus durans	Enterococcus
faecium	1	Yersinia
frederiksenii	Yersinia
pseudotuberculosis

27

• This VITEK®MS identification indicates that the VITEK®MS result is a non-clinically validated organism. These organisms are displayed in the VITEK®MS report as a means of directing additional laboratory testing. Identification of non-clinically validated organisms must be performed with an alternate laboratory method.

Non-clinically validated organisms include:

• · Organisms with insufficient clinical performance data.
• · Organisms not found in human clinical samples as reported in the scientific literature.

Results for non-clinically validated organisms cannot be transmitted from the VITEK "MS to the LIS.

M. Instrument Names:

VITEK®MS

N. System Description:

1. Modes of Operation:

The VITEK®MS system is based on a matrix-assisted laser desorption ionization-time of flight mass spectrometer (MALDI-TOF MS). The VITEK MS analyzes material from microbial cultures to provide organism identification. Microbial specimens are analyzed based on the dynamics of particles ionized by a laser shot in a vacuum tube. The resulting spectrum of mass distribution is interpreted according to an algorithm developed by the Firm.

A portion of a microbial colony from an agar plate is applied to a spot on a VITEK MS-DS target slide. A matrix solution is applied to the spot. The target slide is dried and then loaded into the VITEK® MS instrument. The sample is exposed to multiple laser shots, the matrix absorbs the laser light and vaporizes along with the sample and in the process the sample gains an electrical charge (ionization). Electric fields accelerate and guide the ions into the vacuum tube which separates them according to mass as the smaller molecules fly faster than the larger ones. At the end of the flight path there is a detector which records the number of ions striking it per unit time. The intensity data from the detector is displayed as a function of the time of flight and the result is a series of peaks which correspond to different molecular fragments of sample each having a unique mass to charge ratio. Each unique organism will produce a unique and repeatable mass spectrum. The resulting spectrum of mass distribution will be interpreted by comparing with a to previously acquired known spectral database developed by the Firm to provide organism identification results with a confidence level.

An overview of the workflow is presented in the graphic below along with a table describing the function of each system component. After the colony is chosen and placed on the Target Slide with matrix, all other analysis steps are performed by the VITEK®MS.

28

Workflow step	Target slide	Output Data
Sample Preparation	VITEK MS-DS
target slides are
prepared	The VITEK MS-DS target slide and sample barcodes are read on the
VITEK® MS Prep Station to identify the spots on the VITEK MS-DS
target slides
Target slide data are sent to VITEK® MS Prep and Myla™.
Verify VITEK MS-DS
target slide composition		The VITEK MS-DS target slide description screen is displayed in
Myla ™.
Start Analysis	Target slides are
placed on the
adapter, the
adapter is then
loaded into the
VITEK® MS
instrument and
the analysis is
started.	The VITEK MS-DS target slide barcodes are read on the VITEK® MS
Prep Acquisition Station to indicate the order in which they are
processed by the VITEK®MS.
Review Identification
results		The VITEK® MS Prep identification results are consolidated (if
necessary), displayed and reviewed in Myla ™. The reviewed results are
sent by Myla™ to the LIS if the one-step review process is selected.
Approve consolidated
Identification results and
the corresponding data
entry		If the two-step 'Review and Approve for result Validation' setting is
enabled in Myla™, the VITEK® MS Prep identification results
previously reviewed can then be approved on Myla™ then sent to the
LIS.

29

2. Software:

FDA has reviewed applicant's Hazard Analysis and software development processes for this line of product types:

Yes __________ or No _________

Level of Concern:

Moderate

Software Description:

VITEK®MS Acquisition Station

The VITEK MS Acquisition Station consists of a computer equipped with a barcode reader. It is connected to the VITEK MS instrument via USB, serial and camera ports. The VITEK MS Acquisition Station receives prepared VITEK MS-DS data from the VITEK MS Analysis Server software and acquisition results from the VITEK®MS instrument. It displays the spectra and peak lists and transfers the peak lists to the VITEK MS Analysis Server.

VITEK®MS Prep Station

The VITEK® MS Prep Station consists of a computer equipped with a barcode reader and the VITEK MS Prep Station Hardware. The VITEK® MS Prep Station is used to prepare VITEK MS-DS target slides and to enter VITEK MS-DS slide data into the system software. The VITEK MS slide data are transferred from the VITEK MS Prep Station to the VITEK® MS Analysis Server software which resides within the Myla™ server PC. The VITE® MS Prep Station Hardware is connected via USB to the VITEK® MS Prep Station. It is used to record data on the cassette memory chip: sample ID and card data.

Myla ™

Myla™ is a computer application ("Middleware"), based on Web technology. Myla™ interfaces with a number of the Firms analytical instruments connected to the application and the LLS (Laboratory Information System). Myla™ displays information related to the laboratory workflow and the following functions:

• · Displays system information.
• · Displays ID results from the VITEK®MS
• · Displays the sample positions on the slide for the VITEK®MS
• · Enables VITEK®MS identification results to be sent to the VITEK 2 and/or the LIS, depending on the result validation workflow selected
• · The computer (server) which hosts the Myla™ application also hosts the VITEK® MS Analysis Server that manages the VITEK®MS workflow and the Computation Engine. The VITEK ®MS analysis server sends the acquired data to the computation engine that calculates the identification results. The algorithms and mapping files required for identification are contained within the computation engine.

30

Device Hazard Analysis:

The Risk Management Report documents the results of verification, evaluates the residual risk, and determines whether the benefit of the device outweighs any residual risks. Sections 4.1.12, 4.2.9, and 11.9 contain the Risk Management Plan and Safety Risk Management File, documenting the VITEK®MS. Myla™, and VITEK®MS Plus hazard analysis, respectively.

The Risk Management Plan describes the strategy followed to analyze and manage the risks at the system level and at the sub-systems/components level knowing that it is a continuous process followed during the development cycle and updated as long as the product is on the market. At the system level, the risk analysis is used to identify:

• · The potential hazards linked to the life cycle of the product (from design/manufacturing to product withdrawal). The preliminary requirements document and the system requirements will serve as a basis. The hazards considered include those related to people (patients, consumers, users or third party), property and environment.
• · The part of the system that will be involved in the hazard cause or mitigation. The system shall be seen as an assembly of subsystems (disposables, instrument, user interface software) that interact between themselves, and with external stakeholders (users and LIS). Subsystems are viewed as black boxes and risks linked to the interface have to be identified at this stage.

The objective of the risk management activities is to deliver a risk analysis report, which contains:

• · Device characteristics that could impact safety [ISO 14971]
• Software safety classification [IEC 62304]
• Risk analysis table
• · Risk traceability matrix with design requirements
• · Overall assessment of residual risk

The risk analysis is organized into the following categories:

• System risk analysis
• Instrument risk analysis
• Software risk analysis
• Matrix risk analysis
• · CLSI Auto 11A considerations
• · Connectivity risk assessment

At the sub-system/component level the approach is a bottom-up analysis based upon FMEA and on the hazards already identified at the system level. The sub-system/component detailed risk analysis includes the risks that have been identified at the system level as long as the given subsystem is involved in the risk mitigation or in the cause. Specific risks identified inside each subsystem/component were acceptably addressed. At the end of the process the final system risk was re-assessed based upon the verification and validation of the risk mitigation actions.

The Risk Analysis report identified the causes of all potential hazards associated with the device and the controls that have been developed to mitigate such risks. A remaining residual hazard identified during the final risk analysis and validation testing of the instrument control software showed that the user is able to swap slide bar codes during reading, references to proper workflow and how to scan bar codes are mentioned in the user manual in order to prevent the inaccurate

31

results that cause inappropriate physician action. All other hazards have been successfully mitigated to an acceptable level, and no new additional hazards have been identified.

Architecture Design Chart:

The following graphic shows the architectural layout and relationships of all components which make up the VITEK®MS software.

Image /page/31/Figure/3 description: The image shows a diagram of the functional components of VITEK MS Plus. The diagram is organized in a hierarchical structure, with the top level being "VITEK MS Plus functionnalities". The next level consists of "system continue to provide all IVD functionnalities", "system allows RUO functionnalities in addition", and "SARAMIS improvement by defect fix". The diagram further breaks down these components into more specific functionalities, such as "make identification", "manage own spectra knowledge", and "acquisition customization".

The IVD components of the VITEK ®MS COMBO system, as part of a product linked with Myla™ have interactions with the other Firm manufactured products compatible with Myla™. For example, in the same lab, the VITEK 2 system or the BacT/ALERT system could be added and interconnected with the VITEK ®MS COMBO via Myla™ middleware. These systems can share resources such as: ViLink, BCILink, IVD results common management (like result validation, report generation) in the Myla™ interface. RUO results that are generated by SARAMIS do not have interactions with Myla™ and do not have any in interactions with other bioMérieux systems. Below is a simplified graphic showing the star type communication model Myla™ implements to communicate and control other systems compatible with the interface.

32

Image /page/32/Figure/0 description: The image shows a diagram of the MYLA system and its interactions with other systems. MYLA is shown in the center of the diagram, and it is connected to VITEK MS Plus, VITEK 2, Bact T, and LIS. The diagram also includes a note that MYLA controls the interaction between systems, and that RUO results are not sent to MYLA and stay in VITEK MS Plus.

33

1.0 SOFTWARE DEVELOPMENT ENVIRONMENT

The Myla™ V3.0.0 software was developed following an iterative mode, before entering into formal verification and validation.

The software project life cycle consists of following three phases.

• · Design phase
• · Implementation phase
• · Verification phase

The final validation was performed by the Myla™ Team members belonging to the Product Validation functional area. Validation is done at the system level by integrating different systems including VITEK® MS. The software development cycle follows the standard IEC 62304.

Software Requirements Specification (SRS):

This specification summarizes the functional specifications for the VITEK®MS device software. This document defines requirements for the externally observable functions of the VITEK®MS Software. Three software product requirements were merged into a single summarized document and include the:

• · Sample Preparation Station
• MS-ID Instrument Control software
• · MS-ID Analysis Software

Traceability Analysis:

The Traceability Analysis Matrix lists the software requirements identified in the VITEK®MS and Myla™ Software Specification documents and relates these to the hazards that have been identified and to verification and validation testing.

The Traceability Analysis Matrix for the VITEK®MS Software and Myla™ Middleware are included in Sections 4.1.10, 4.2.7. The traceability matrix includes traceability from the PRD requirements to verification and validation test cases. It also includes traceability from the PRD to SRS. The SRS requirements were inherited from a third party software supplier and did not change during development.

Verification and Validation Testing:

This final validation report summarizes the results of the validation done on the mass spectrometry system (VITEK® MS V1.0, V1.1, V2, Myla™ V2, V2.2, V3.0, and V3.1). It includes the rationale, a brief description of the protocol, and a summary of the results including any deviations and justifications for any unresolved anomalies generated during validation.

The verification and validation test reports are acceptable as presented in the Sections listed above.

34

Software Item	Reviewed Revision
Acquisition Station Software	1.4.2
Prep Station Software	2.3.1
Knowledge Base	VITEK® MS KB v2.0
Computation Engine	1.1.0
Myla ™	2.4

Revision Level History:

Unresolved Anomalies:

During the iterative verification testing of Myla™, there was a reduction of anomalies (582 total anomalies were repaired) and an increasing percentage of the testing passed verification. Following the 12th and final round of testing, 100 % of the unit and performance testing passed verification while 86% of the integration testing passed. The 14% of failures led to 42 unresolved anomalies. These anomalies were evaluated during an anomaly review board (ARB). Of the 42 resulting anomalies from verification testing, none were a level 1 or 2 (serious blocking anomalies), 10 were level 3 that had clear workarounds for the customer, and the remaining anomalies were either a minor inconvenience or transparent to the user. Only 4 of these 42 anomalies affected the VITEK "MS system directly and 2 of the 42 anomalies have been repaired in Myla™ V3.1. As the majority of these anomalies were considered minor and workarounds were in place for others, Myla™ 3.0 was considered verified and ready for validation

The system verification performed on the VITEK®MS components included: the analysis server software, prep station software, analysis server and computation engine, acquisition software, target slides, matrix, biological samples, Myla™, the LIS connection, and VITEK 2 connection. The svstem verification showed the testing done on the VITEK®MS system from versions 1.1 to 2.0 which is a complete testing of all the components in the VITEK®MS V2.0 system. Most of the system verification testing was done in V1.1. System verification was done on changes between V1.1 and V2.0. The verification strategies for the VITEK®MS V1.1 and 2.0 were organized in increments, by integrating more and more sub-components of the global system. In addition, several verification rounds were done to repair anomalies found during previous rounds. As mentioned above, the anomaly DCR 15190 found in the acquisition station was not verified at the system level but the software was verified and validated. This anomaly does not affect results. The system was considered verified at the system level.

For the VITEK®MS Software DCR's which were not fixed, a justification of why each DCR was not addressed and a severity was reported.

Any future issue or anomaly coming from the field will be analyzed with the help of the software manager, in collaboration with system engineers and Firm customer representatives through an Anomaly Review Board. The level the severity of the defect will drive the investigation activities and root cause analysis. Issues will be tracked and if a change is deemed necessary an impact analysis will be done to assess to potential effect on the software design, system, risks and Verification & Validation (V&V). Regression testing will be done in accordance to the potential impacts. Any release of a change shall be accepted by the Firm's QA/Regulatory Compliance teams.

35

Off the Shelf Software (OTS) or Software of Unknown Pedigree:

There were a total of 22 OTS applications reported in response to the Additional Information request. The manufacturer, released revision, and general and technical justification for use was included in the OTS report. The user does not directly interact with any OTS application and therefore no additional training is needed. The Firm has reported what testing was done during V&V activities and either indicates individual test cases as validation evidence or states how the OTS was validated as part of the system validation. A matrix is provided linking together which OTS is used by each VITEK®MS software component.

The implementation of the VILINK component is reported to use 3 OTS applications which are sufficiently documented. The VILINK provides remote access to the medical device via a periodic HTTPS connection. The security of this connection is described and documentation related to the use and cybersecurity features of VILINK are provided.

The 32 requirements of the CLSI AUTO-11AE standard were assessed. The software architecture has been designed to minimize IT security risks and the remaining level of risk is minor.

An OTS specific Risk Analysis is provided showing that all remaining risks are categorized as minor.

EMC Testing:

The system has been tested for compliance with the following standards:

Conformance to BS EN 61326-1. BS EN 61326-2-6:2006: Electrical equipment for measurement, control and laboratory use was reported. Additional conformance reported for testing of disturbance requirements including EM Field Immunity, Surge Immunity, Power magnetic field, Voltage dips and short interruptions according to the appropriate sections of IEC 610000-4.

Conformance to IEC 61010-1:2001 Safety requirements for electrical equipment for measurement, control and laboratory use Part 1was reported.

3. Specimen Identification:

The microorganisms to be identified must first be isolated on a suitable culture medium. Appropriate media, including commercial media most frequently used in clinical microbiology laboratories such as Columbia blood agar, should be used. The VITEK ®MS Prep Station software can be used to prepare samples for VITEK®MS and other systems, therefore several workflows are available to cover all possible analysis situations

The VITEK®MS Prep Station consists of a computer equipped with a barcode reader, and the VITEK MS®Prep Station Hardware. The VITEK MS Prep Station is used to prepare VITEK MS-DS target slides and to enter VITEK MS-DS data. These data are transferred from the VITEK® MS Prep Station to the VITEK®MS and Myla™ systems. The VITEK®MS Prep Station Hardware is connected via USB to the Prep Station.

36

VITEK®MS Sample Preparation screen

The VITEK®MS workflow begins with preparing the VITEK MS-DS target slides using the VITEK® MS Prep Station. Place a VITEK MS-DS target slide on the bench in front of the VITEK® MS Prep Station. The Sample Preparation screen on the VITEK®MS Prep Station is used to enter data linking specimens to VITEK MS-DS target slides and optionally to the VITEK 2 test cards. Data can be entered by scanning bar codes on the target slides and cards or by manually typing information in the appropriate fields. Once a bar code is scanned, the cursor will automatically move to the next required field.

VITEK ®MS Target Slide Graphic

Once a target slide ID has been entered in the Enter Slide ID field, the system dynamically displays the status of a VITEK MS-DS target slide. Each time a Sample ID is linked with a VITEK MS spot, the system updates the VITEK®MS target slide graphic and displays them as colored target slide spots (light blue for Fungi and dark blue for Bacteria). To display specimen information for a specific VITEK®MS target slide spot, the user clicks on a blue target slide spot. The user can then validate the entered sample information by clicking on the Validate button on the Prep Station screen or cancel all entered sample information by clicking on the Cancel button.

To further verify if the data entered for every spot are correct, the user can click on a filled target slide position. The software will then display the accession ID for the selected spot. In case of an error, all data entered for the selected spot can be erased. Once the VITEK MS-DS target slide is full or when sample preparation is finished, the user transfers the target slide information to the VITEK MS system by clicking on the "Send Slide" button on the target slide graphic

4. Specimen Sampling and Handling:

All specimens, microbial cultures and inoculated products should be considered infectious and handled appropriately. Aseptic technique and usual precautions for handling organisms should be observed throughout this procedure. Refer to "CLSI M29-A. Protection of Laboratory Workers From Occupationally Acquired Infections; Approved Guideline - Current revision". For additional handling precautions, refer to "Biosafety in Microbiological and Biomedical Laboratories -CDC/NIH -Latest edition".

Isolated bacterial colonies are applied to a single well of a disposable, barcode-labeled target slide (Vitek MS-DS; bioMérieux, Inc.) using a 1.0 ul loop. The sample is applied as a thin layer to the target slide spot. For bacteria, the sample is overlaid with 1.0 ul of a saturated solution of alphacyano-4-hydroxycinnamic acid matrix in 50% acetonitrile and 2.5% trifluoroacetic acid (Vitek MS-CHCA; bioMérieux, Inc.), and air dried. For yeasts, a 1 ul loop is also used to apply the yeast sample to the target slide spot. 0.5 ul of MS-FA is added to the yeast and allowed to evaporate. 1.0 ul of MS-CHCA is then added to the same spot and air dried. A new pipet tip is used for each spot.

Prepared VITEK MS-DS slides must be tested within 48 hours. Prepared slides should be stored at room temperature until they are tested.

37

5. Calibration

E. coli ATCC 8739 is used to as a calibrator. This organism is deposited with VITEK MS-CHCA matrix on positions: xA1, xB1, xC1, of the MS-DS slides dependent on the number of samples tested (one calibrator per acquisition group of 16 spots). The VITEK®MS goes to the calibration spot in an acquisition group and performs a calibration. If the calibration passes, the instrument goes to the first spot in the acquisition group. If the calibration fails, an error is reported and VITEK®MS proceeds to the next acquisition group without collecting sample spectra have been acquired from each sample spot in an acquisition group, the calibration spot is checked again. The calibration sample should provide E. coli identification at 99.9% in Myla™ software.

6. Quality Control

Two organisms are used for positive quality control. Matrix alone is used for the negative control. The quality control strains are as follows:

	Expected Result
Enterobacter aerogenes ATCC® 13048	Enterobacter aerogenes
Candida glabrata ATCC MYA-2950	Candida glabrata
Negative Control (matrix)	No Identification

NOTE: If the negative control gives does not give the expected result, users need to visually check the surface of the VITEK MS-DS target slides to ensure the slides are clean and repeat testing with new slide.

• O. Other Supportive Instrument Performance Characteristics Data Not Covered In the "Performance Characteristics" Section above:

1. Mixed Culture Study

A strain of Staphyloccocus aureus direct from a colony, at minimum and maximum detection concentrations, mixed with other organisms with different ratios. Maximum concentrationwere standardized at 7 McFarland. Plate counts were performed to verify densities. Minimum concentrations suspension thresholds were evaluated at LoD of test organism. The following species were tested in this study: Staphyloccocus aureus, Pseudomonas aeruginosa, Escherichia coli, Corynebacterium jeikeium and Candida glabrata. VITEK®MS allowed an answer in:

• 68.2% (30/44) of cases, an identification of the more concentrated species in single ● choice.
• . 11.4% (5/44) of cases, an identification of the less concentrated species in single choice (cases observed with C. jeikeium, which could be due to the fact that the limit of detection for C. jeikeium (6 McF) is close to the maximum tested concentration (7 McF), and
• 20.5% (9/44) of cases, a Low Discrimination between both tested species. ●

The user should follow manufacturer instructions to test pure isolated colonies only.

38

2. Viability Study:

A viability study to verify that there is no biological risk for the user to handle the spotted VITEK MS-DS slide once the VITEK MS-CHCA (bacteria) or VITEK MS-FA /VITEK MS-CHCA (yeast) is added was performed. A panel of strains comprising Gram negative, Gram positive and yeast groups were inoculated onto different media according to their growth requirements and incubated in appropriate conditions. Each organism was tested on the VITEK®MS using 24 hour and 3 day colony growth. The viability study showed that bacteria and yeast from a fresh culture spotted on the VITEK MS-DS target slides are not viable after the addition of CHCA matrix (bacteria) or CHCA matrix and formic acid (yeast).

NOTE: Although sporulation medium has not been validated for use with the VITEK®MS, studies demonstrated Bacillus subtilis from the sporulation medium (incubated for at least 4 days) is viable even after the addition of CHCA matrix. The viability of Bacillus subtilis from the sporulation medium appeared to be due to the presence of spores, after several days of incubation, which are able to survive in unfavorable conditions.

Users are instructed that all specimens, microbial cultures and inoculated products should be considered infectious and handled appropriately. Aseptic technique and usual precautions for handling organisms should be observed throughout this procedure. Refer to "CLSI M29-A, Protection of Laboratory Workers From Occupationally Acquired Infections: Approved Guideline - Current revision". For additional handling precautions, refer to "Biosafety in Microbiological and Biomedical Laboratories - CDC/NIH -Latest edition".

3. Run Failures from Clinical Trial:

Calibration failures (10 events), QC failures (4 events) and instrument failures (10 events) were documented and resolved during the clinical trial. Most calibration and OC failures were due to suboptimal sample preparation.

P. Proposed Labeling:

The labeling is sufficient and satisfies the requirements of 21 CFR Part 809.10, 21 CFR 801.109, and the special controls.

39

Q. Potential Risks and Required Mitigation Measures

Identified Potential Risk	Required Mitigation Measures
Incorrect identification of a pathogenic
microorganism can lead to improper patient
management.	1) Premarket notification submissions must
include detailed documentation for device
software, including, but not limited to,
standalone software applications and
hardware-based devices that incorporate
software.

2. Premarket notification submissions must
   include database implementation
   methodology, construction parameters and
   quality assurance protocols. |
   | Failure to correctly interpret test results | 1) A detailed explanation of the interpretation of
   results and acceptance criteria must be
   included in the device's 21 CFR 809.10(b)(9)
   compliant labeling. |
   | Failure to correctly operate the instrument | 1) As part of the risk management activities
   performed as part of your 21 CFR 820.30
   design controls, you must document an
   appropriate end user device training program
   that will be offered as part of your efforts to
   mitigate the risk of failure to correctly operate
   the instrument.

3. Premarket notification submissions must
   include details on the appropriate end user
   device training program that will be offered
   while marketing the device. |

40

R. Benefit/Risk Analysis

Summary
Summary of
the Benefit(s)	The primary benefit from this device is more rapid identification of microorganisms
from cultured material. In the setting of a critically ill patient or a patient infected by
an unusual/unexpected pathogen, more rapid identification of a possible pathogen
may ensure appropriate antibiotic use earlier; similarly, identification of a possible
microbial contaminant (or non-pathogenic microorganism) may lead to earlier
withdrawal of unnecessary antibiotics.
Summary of
the
Risk(s)	The risks from this device include incorrect identification of a pathogenic
microorganism by the device. As noted earlier, device performance testing suggests
that the overall risk of an incorrect identification is low, and that an incorrect
identification may not necessarily translate to patient harm. Mitigating factors,
including the nature of specific misidentification, patient clinical status, and
experience of the clinical microbiologist (the latter is particularly important); in
addition, antibiotic susceptibility testing should mitigate the risk that a patient will
be treated with an antibiotic that is inactive against the isolated pathogen. (It is also
possible that antibiotic susceptibility testing will raise suspicion that incorrect
microorganism identification has occurred.) Overall, risk of patient injury from use
of the device is low and should not be greater than alternatives currently used by
clinical microbiology laboratories.
	Although a 'no identification' result may delay microorganism identification, this
result would likely default to additional testing of the same sample or testing by an
alternative method, and likely not present added risks relative to current clinical
microbiology practice.
	Special controls regarding devices of this type introduce additional mitigations
against possible device misidentification errors by requiring that premarket
submissions include detailed documentation of device software (including, but not
limited to, standalone software applications and hardware-based devices that
incorporate software), and database implementation methodology, construction
parameters and quality assurance protocols.
Summary of
Other Factors
Microorganism identification is a core clinical laboratory function and is a mainstay of medical practice. The VITEK® MS reflects further evolution in the ability of laboratories to more rapidly identify pathogenic organisms and represents technology that, combined with widespread introduction of molecular technologies, will further add to the fundamental changes in clinical microbiology laboratory practice that have occurred over the past 10 – 15 years. Microorganism identification has an important role beyond individual patient care: it is essential for hospital infection control, for identification of possible outbreaks, and for bioterrorism alerts. To the extent that the VITEK®MS provides more rapid microorganism identification and the benefits that accrue, this is a potential advance over existing microbiological methods but not a complete replacement given the frequency of no identification results; this is well captured by the title of recent published study of VITEK®MS performance: Comparison of Vitek®MS (MALDI- TOF) to standard routine identification methods: an advance but no panacea. (Harris, P et al; Pathology 44(6), 583-585 (October, 2012). As noted earlier, device errors can arise from failure to operate the instrument correctly, or more broadly, failure to correctly interpret test results. These are mitigated by an appropriate end user device training program that will be to mitigate the risk of failure to correctly operate the instrument and by the device's 21 CFR 809.10(b)(9) compliant labeling where there is a detailed explanation of the interpretation of results and acceptance criteria.
Conclusions
Do the
probable
benefits
outweigh the
probable
risks?	Yes.

41

S. Conclusion:

The information provided in this de novo submission is sufficient to classify this device into class II under regulation 21 CFR 866.3361 with special controls. FDA believes that special controls, along with the applicable general controls, provide reasonable assurance of the safety and effectiveness of the device type. The device is classified under the following:

42

• Mass spectrometer system for clinical use for the identification of microorganisms Device type:
  Class: II (special controls)

Regulation: 21 CFR 866.3361

• Identification. A mass spectrometer system for clinical use for the (a) identification of microorganisms is a qualitative in vitro diagnostic device intended for the identification of microorganisms cultured from human specimens. The device is comprised of an ionization source, a mass analyzer and a spectral database. The device is indicated for use in conjunction with other clinical and laboratory findings to aid in the diagnosis of bacterial and fungal infections.
• (b) Classification. Class II (special controls). Mass spectrometer system for clinical use for the identification of microorganisms must comply with the following special controls:
  • 1. Premarket notification submissions must include detailed documentation for device software, including, but not limited to, standalone software applications and hardware-based devices that incorporate software.
  • 2. Premarket notification submissions must include database implementation methodology, construction parameters and quality assurance protocols.
  • 3. A detailed explanation of the interpretation of results and acceptance criteria must be included in the device's 21 CFR 809.10(b)(9) compliant labeling.
  • 4. As part of the risk management activities performed as part of your 21 CFR 820.30 design controls, you must document an appropriate end user device training program that will be offered as part of your efforts to mitigate the risk of failure to correctly operate the instrument.
  • 5. Premarket notification submissions must include details on the appropriate end user device training program that will be offered while marketing the device.